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1. Summary     
 
Multiple sclerosis (MS) is an autoimmune inflammatory disease of the central 
nervous system (CNS). Myelin antigen(s) specific T cells, B cells, and antibodies are 
thought to play a role in the pathogenesis of MS. While the influence of autoantigen 
specific CD4+ T cells has been extensively studied in animal models, the relevance 
of autoantigen specific B cells and their interactions with pathogenic T cells are 
largely unknown.  
The original aim of the present study was to create a new mouse model with 
which to investigate the interaction of myelin autoantigen specific B and T cells and 
their role in MS pathogenesis. The study was further expanded to analyze the nature 
and triggers of spontaneous disease and similarity of the mouse lesion pattern to 
that in human disease. 
The double-transgenic mouse (“Devic mouse”) strain presented here contains 
myelin oligodendrocyte glycoprotein (MOG)-specific T as well as B cells. A 
significant proportion (>50%) of these mice showed spontaneous experimental 
autoimmune encephalomyelitis (EAE)-like disease at a young age. In contrast, all 
single transgenic littermates were free of clinical disease. Spontaneous EAE 
requires both MOG-specific T and B cells, since the breeding of MOG-specific Ig 
heavy chain knock-in mice with ovalbumin specific T cell receptor (TCR) transgenic 
mice did not develop any disease.  
Histological analysis of the CNS of affected mice revealed restricted localization 
of lesions in the spinal cord and optic nerves as well as severe demyelination and 
axonal damage that spared brain and cerebellum. The inflammatory infiltrates were 
predominantly composed of macrophages and CD4+ T cells, but occasionally also 
eosinophils. This peculiar localization of the demyelinating lesions and infiltration 
profile differ from classic EAE and is reminiscent of Devic’s neuromyelitis optica, a 
variant of classic MS in humans. 
It is not well understood what triggers the initiation of spontaneous EAE. The 
microbial environment does not significantly affect the clinical disease. Stimulation of 
the innate immune system with toll-like receptor (TLR) ligands or depletion of 
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putative regulatory cells did not significantly affect EAE development. The (re-) 
activation of lymphocytes in sick Devic mice mainly occurs in the CNS without 
evidence of priming in the peripheral lymphoid organs. 
 MOG-specific B and T cells cooperate by means of several mechanisms. MOG-
specific B cells, which bind MOG but not the immunodominant peptide MOG 35-55 
via their surface immunoglobulin (Ig), efficiently presented even high dilutions of 
MOG to T cells. This resulted in the enhanced proliferation of T and B cells as well 
as rapid activation. Stimulated T, but not B cells, secreted large amounts of Th1 
cytokines IFNγ and IL-2 along with small amounts of Th2 cytokine IL-5. In addition, 
MOG-stimulated T and B cells expressed a set of co-stimulatory molecules, which 
further help to modulate the proliferation and activation. Surprisingly, the double-
transgenic Devic mice, but not their single transgenic littermates, had high titers of 
MOG-specific IgG1 antibodies in the serum, which indicates a previous encounter 
with antigen in vivo. However, similar MOG-specific serum IgG1 titers were present 
irrespective of the clinical status. The transfer of EAE by Devic splenocytes in 
immunodeficient mice or by bone marrow reconstitution in wild-type mice further 
supported the in vivo cooperation of MOG-specific T and B cells to induce 
spontaneous EAE. 
In summary, Devic mice show several salient features that are important for study 
of the pathogenic mechanisms of CNS autoimmunity. As a model of spontaneous 
autoimmunity, they may allow us to study the triggering factors of autoimmunity as 
well as the factors that determine restricted infiltration of immune cells into the CNS. 
In addition, the model may be useful for validating novel therapies for autoimmune 
CNS diseases.  
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2. Introduction 
 
The immune system normally eliminates threats from invading pathogens, but at 
times it directs its potent reactivity against the body’s self-constituents, causing 
autoimmunity. Autoimmune diseases represent a group of diseases that often 
involve distinct anatomical regions. They are estimated to affect approximately 5% of 
the world population (Davidson and Diamond, 2001; Jacobson et al., 1997), causing 
morbidity and mortality on an immense scale. Although the pathogenic mechanisms 
of many autoimmune diseases have not been clearly defined, it is widely believed 
that they are caused by a combination of several factors such as genetic 
susceptibility and environmental triggers. Epidemiological studies strongly suggest 
that allergic and autoimmune diseases are clearly on the rise in the developed 
countries.  
Infectious agents are involved in a complex relationship with autoimmunity. While 
the absence of infection favors autoimmunity, its presence can also precipitate 
autoimmunity (Bach, 2002; Christen and von Herrath, 2005). Clinically, autoimmune 
diseases are broadly classified as systemic and organ-specific autoimmune 
diseases. An example of systemic disease is systemic lupus erythematosus; organ-
specific autoimmune diseases include multiple sclerosis, type I diabetes, and 
rheumatoid arthritis.  
2.1 Multiple sclerosis (MS) 
2.1.1 Definition 
 
Multiple sclerosis is the major chronic inflammatory disease of the central nervous 
system (CNS); it affects more than 1 million people, mainly in Western societies. MS 
is more prevalent in females than males (~1.6: 1), often develops during young 
adulthood, and is generally present throughout life. Typical disabilities caused by MS 
include paralysis, lack of co-ordination, sensory disturbances, and impaired vision 
and cognitive function (Sospedra and Martin, 2005). It is believed to be an 
autoimmune-mediated disorder in which autoreactive cells directed against 
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components of the myelin sheath attack and destroy the myelin (Noseworthy et al., 
2000). 
2.1.2 Clinical course 
 
MS occurs in various clinical forms and can be distinguished by its clinical course. 
These forms include primary-progressive (PP)-, secondary-progressive (SP)-, 
relapsing-remitting (RR)-MS, and progressive-relapsing (PR)-MS (Figure 2.1). Most 
commonly, MS patients develop an RR course, during which episodes of acute 
worsening of the disease alternate with periods of recovery, and between relapses 
the course of the disease is stable. Relapses or “attacks” typically occur with 
symptoms that develop over hours to several days, persist for several days or 
weeks, and then gradually dissipate. The traffic of activated, myelin-reactive T cells 
within the CNS causes acute inflammation associated with edema, which may 
explain the periodicity of the relapses. However, in a minority of patients, disease 
progresses steadily from the onset, without acute attacks and involving a gradual 
neurologic deterioration (PP-MS). 
 
Figure 2.1 
Schematic depiction of clinical course of multiple sclerosis (modified from Kieseier and Hartung, 
2003).  
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SP-MS is characterized by  gradual neurologic deterioration with or without further 
acute relapses in patients who previously had RR-MS. PR-MS typically shows 
disease progress from the onset, acute relapses with or without full recovery, and 
periods of continuous progression between relapses (Sospedra and Martin, 2005; 
Kieseier and Hartung, 2003). 
2.1.3 Pathology 
 
Chronic MS brain tissue has sharply demarcated demyelinated plaques 
throughout the CNS white matter. It exhibits a certain predilection for the optic 
nerves, periventricular regions, brainstem, cerebellum, and spinal cord (Lassmann et 
al., 2001). Some patients develop a so-called clinically isolated syndrome, for 
example, optic neuritis, brainstem dysfunction, or incomplete transverse myelitis as 
their first event. There is also substantial axonal injury with axonal transactions 
throughout the MS lesions. The inflammatory lesions are dominated by inflammatory 
infiltrates in the perivascular area with extensive demyelination. Perivascular 
infiltrates are composed of oligoclonal T cells consisting of CD4+, CD8+, γδ T cells, 
macrophages with occasional B cells and plasma cells (Hafler, 2004; Hauser et al., 
1986; Traugott et al., 1983). Activated macrophages in the center of the plaques 
contain myelin debris, and the number of oligodendrocytes is reduced.  
In a recent pathological study of a large series of actively demyelinating MS 
lesions, four histopathological patterns were defined on the basis of myelin loss, the 
geography and extension of plaques, the pattern of oligodendrocyte destruction, and 
the evidence of complement activation. All actively demyelinating lesions had 
inflammatory infiltrates composed mainly of T cells and macrophages. Pattern I 
(macrophage-associated demyelination) lesions contained toxic products of 
activated macrophages and microglia associated with degenerating myelin. This 
suggests that T cell-mediated inflammation is involved with macrophage/microglia 
activation. Most of the mouse models of autoimmune encephalomyelitis show a 
close resemblance to this pattern of myelin destruction. Pattern II (antibody-
mediated demyelination) lesions contain immunoglobulin and activated complement 
deposited at sites of active myelin destruction together with activated 
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macrophages/microglia. These lesions are very similar to the experimental 
autoimmune encephalomyelitis (EAE) models that are induced by sensitization with 
myelin oligodendrocyte glycoprotein (MOG). In pattern III (distal 
oligodendrogliopathy-associated demyelination) lesions, a rim of myelin is frequently 
preserved around inflamed blood vessels within the demyelinated plaque. The 
striking feature of these lesions is a preferential loss of myelin-associated 
glycoprotein (MAG), whereas other myelin proteins (proteolipid protein (PLP), myelin 
basic protein (MBP), and 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNPase)) are 
still present within the partly damaged myelin sheaths. The degeneration of distal 
oligodendrocyte processes, followed by oligodendrocyte apoptosis and 
demyelination, are commonly observed in virus-induced white matter diseases as 
well as in white matter strokes. This suggests that the possible mechanism is 
secondary ischemic damage of the white matter. Pattern IV (primary oligodendrocyte 
degeneration) lesions are very infrequent in MS. In this pattern, demyelination is 
associated with oligodendrocyte death in a small rim of periplaque white matter, 
adjacent to the zone of active myelin destruction (Lucchinetti et al., 2000; Lassmann 
et al., 2001). Although this is true for classic MS, some variants of the disease, e.g., 
Devic’s disease (see below), exhibit lesions restricted to the optic nerves and spinal 
cord (Cree et al., 2002). 
2.2 Devic’s neuromyelitis optica (NMO): a variant of classic MS 
 
In contrast to the classic MS subtypes, patients with neuromyelitis optica, also 
termed Devic’s disease, develop both bilateral or unilateral optic neuritis and myelitis 
without any involvement of the brain. It is still being debated, whether Devic’s 
disease is a variant of MS or a distinct neurological disorder (Minagar et al., 2002). 
Interestingly, this kind of opticospinal MS is a common inflammatory demyelinating 
disease in Asia. In Japan, for example, it accounts for 15-40% of MS cases (Kira, 
2003). The majority of Devic’s patients develop optic neuritis and later acquire 
myelitis. The intervals between both manifestations vary. Monophasic and relapsing 
variants of Devic’s disease have been described. Recurrent attacks are associated 
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with female sex, older age at onset, longer intervals between neuritis and myelitis, 
and the presence of systemic autoimmune disorders (Wingerchuk et al., 1999).  
In Devic’s disease, acute spinal cord lesions develop with diffuse swelling and 
softening extending over multiple spinal segments. Occasionally they may involve 
the entire spinal cord, showing a patchy or continuous distribution. As in MS, 
extensive macrophage infiltration is associated with myelin and axonal loss that 
occurs with necrosis of both gray and white matter (Mandler et al., 1993). A detailed 
pathological analysis of 80 NMO lesions recently revealed that demyelinating lesions 
are associated with perivascular deposition of Ig, local activation of complement, and 
marked eosinophilic infiltration (Lucchinetti et al., 2002). The factors that determine 
this selective attack on only the optic nerve and spinal cord are not known. Are the 
structure and stability of the blood-brain barrier (BBB) responsible or are there 
regional differences in the ability of the CNS to process and present antigen to the T 
cells? 
There is no selective diagnostic marker, and no disease autoantigen has been 
clearly associated with Devic’s disease. An NMO-specific IgG autoantibody, which is 
not present in other inflammatory diseases of the CNS including classic MS, was 
recently identified in some Devic’s patients. These NMO-IgGs seem to specifically 
localize in the BBB (Lennon et al., 2004). Interestingly, these NMO-IgGs have been 
shown to cross-react with mouse aquaporin-4 (AQP4) present in the CNS, kidney, 
and gut tissues. On the basis of these findings it has been suggested that AQP4 
could be a potential target autoantigen (Lennon et al., 2005). AQP4 is an integral 
membrane protein that is present on astrocytic end-feet of the CNS, and is 
associated with the dystrophin-associated proteins. It is the predominant water 
channel in the CNS and has been implicated in pathophysiological conditions such 
as brain edema after intoxication (Vajda et al., 2002) and focal cerebral ischemia 
(Saadoun et al., 2002; Agre and Kozono, 2003). However, the widespread 
expression of AQP4  in the CNS and periphery does not explain the restricted lesion 
distribution in NMO patients (Badaut et al., 2002).  
On the basis of animal experiments and the presence of MOG-specific antibodies 
in NMO patients, the myelin oligodendrocyte glycoprotein (MOG) has also been 
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suggested to be a potential target autoantigen. Brown Norway (BN) rats immunized 
with MOG reproduce several features of NMO. Lesions are spread around the optic 
nerve, and there is fulminant EAE in the spinal cord with widespread demyelination 
and axonal injury. Importantly, demyelination is also associated with large numbers 
of eosinophils and deposition of complement, both of which are strikingly similar to 
human NMO (Stefferl et al., 1999; Storch et al., 1998).  
2.3 Disease etiology 
 
The etiology of MS remains unclear, but evidence for the contribution of genetic 
factors is unequivocal. MS may also require additional environmental triggers. 
2.3.1 Genetic factors 
 
The role of genetic factors in a person’s susceptibility to MS remains complex and 
poorly understood. The highest prevalence of MS is found in northern Europe and 
North America. Its low prevalence in Asia and Africa suggests that genetic factors, 
ethnic background, and environmental factors contribute to susceptibility to the 
disease. Population, family, and twin studies show that the prevalence is 
substantially increased in family members of MS patients. For example, the risk to 
develop MS and the concordance rate in monozygotic twins are much higher than 
among dizygotic twins (Dyment et al., 2004). Although no clear disease-causing 
genes have been identified, whole genome screens in multiple families of MS 
indicate that a considerable number of genes confer susceptibility to MS; the 
strongest linkage is to human leukocyte antigen (HLA) class II (Dyment et al., 2004; 
Sawcer et al., 1997). Genetic linkage studies showed that there is a significant 
association of HLA class II alleles HLA-DRB1*1501 and HLA-DQB1*0601 with MS 
(Olerup and Hillert, 1991). HLA class II genes may confer a risk of MS by several 
mechanisms. Disease-associated HLA molecules can preferentially present myelin 
peptides. In addition, several reports showed an association of genes such as T-cell 
receptor (TCR) beta, CTLA4 (Cytotoxic T-lymphocyte-associated protein 4), ICAM1, 
CCR5, and CD45 with MS (Dyment et al., 2004).  
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The difference in the disease incidence between males and females (~1.6: 1) also 
suggests that hormonal variables are risk factors. This view is supported by several 
observations: the lower relapse rates during pregnancy; the rebound after 
postpartum; the worsening of MS during menstruation; the correlation of high 
estradiol and low progesterone with increased magnetic resonance imaging (MRI) 
disease activity; the gender differences in EAE, an animal model of MS; the 
protective effect of testosterone; and the therapeutic effects of estriol in RR-MS. The 
precise mechanisms by which sex hormones influence MS susceptibility are not 
known, but the stimulatory effects of estrogens on proinflammatory cytokine 
secretion and the opposite effects of androgens are probably represent one 
mechanism (reviewed in Sospedra and Martin, 2005).  
2.3.2 Environmental factors 
 
Among putative environmental factors, both infectious (virus and bacteria) agents 
and lifestyle influences have been proposed to induce or contribute to disease 
expression (Coo and Aronson, 2004). Many studies have suggested an association 
between episodes of MS exacerbation and concomitant viral or microbial infections. 
Suitable candidates among the viruses are herpesviruses or retroviruses, which 
induce persistent infection; they have been widely studied in MS (Gilden, 2005).  
Herpesviruses are neurotropic and of particular interest in MS studies. Human 
herpesvirus 6 (HHV-6) and Epstein-Barr virus (EBV) are the leading candidates. 
Human herpesviruses (HHV-6 and HHV-8) have been reported to be present in 
active MS plaques (Soldan et al., 1997). The seroprevalence for both is high, i.e., 
>80% for HHV-6 and 90% for EBV. Recently, the probing of cerebrospinal fluid 
(CSF) and serum IgG antibodies from MS patients revealed cross-reactivity to two 
EBV proteins, BRRF2 and EBNA-1 (Cepok et al., 2005). In addition, the reactivation 
of latent EBV infections correlated with MS relapses (Wandinger et al., 2000).  
Infectious agents could induce MS by several mechanisms, including molecular 
mimicry and bystander activation. Molecular mimicry is the term coined for the 
activation of autoreactive cells by cross-reactivity between self-antigens and foreign 
agents (Oldstone, 2005). It involves the potential reactivity of T and B cells with 
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epitopes shared by infectious agents and self-antigens. During thymic selection, the 
recognition of self-antigens by T cells at intermediate affinity leads to positive 
selection. These T cells are exported to the periphery. Self-reactive T cells, which 
recognize the antigenic epitopes shared by self and infectious agents, could be 
activated during infection and then migrate across the BBB to infiltrate CNS and 
damage the brain tissue, leading to the development of autoimmune disease. 
Although examples of such stringent homology have been reported for MBP, a 
myelin antigen, and viruses (Fujinami and Oldstone, 1985), the occurrence of such 
complete matching is a rare event. In addition, protein cleavage is required to 
generate such a perfect matching epitope (Figure 2.2). Wucherpfennig & Strominger 
showed, however, that the MBP-specific T cell clones (TCC) derived from MS 
patients could be activated by viral and bacterial peptides that shared a major 
histocompatibility complex (MHC) binding motif with MBP. They confirmed the 
prediction that complete sequence homology was not required for cross-recognition 
(Figure 2.2; Wucherpfennig and Strominger, 1995). Further, data on crystal structure 
showed that a T cell receptor (TCR) from an MS patient recognized both MBP and 
EBV-derived peptide (Lang et al., 2002). Although these findings demonstrate that 
molecular mimicry could explain the link between infection and MS, evidence for this 
phenomenon in human autoimmune diseases is still scarce. 
 
Figure 2.2  
Evolution of molecular mimicry. Sequence homology between MBP and cross-reactive foreign 
antigens, hepatitis B virus polymerase (HBV-P), and herpes simplex virus (HSV) terminase.  
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Bystander activation assumes that autoreactive cells are activated due to non-
specific inflammatory events that occur during infections. Toll-like receptors (TLR), 
which recognize molecular patterns of infectious agents, superantigens that bind 
TCR outside the peptide binding groove, and inflammatory cytokines released during 
infection can also induce potent TCR-independent bystander activation of 
autoreactive T cells. The second category involves the unveiling of host antigens 
and the adjuvant effect of infectious agents on antigen-presenting cells (APCs). 
Indeed, activation of APCs by TLR9 or TLR4 ligands in PLP 139-151 TCR 
transgenic mice with a genetically resistant B10.S background resulted in the 
development of autoimmunity (Waldner et al., 2004). 
2.4 Target autoantigens in MS and EAE 
 
Pathological observations made in MS clearly indicate that the disease process is 
mainly concentrated in myelinated areas of the brain and spinal cord. Seminal 
observations from Rivers, who showed that injection of spinal cord or brain 
homogenates into healthy primates caused a disease similar to MS, also further 
supported the view that the target antigens are primarily located in the myelin 
sheaths of the CNS white matter. Many decades later many investigators showed 
that immunization of susceptible animals with purified and defined components of 
myelin sheath induced the disease (Wekerle et al., 1994). Several candidate 
autoantigens are present in the CNS white matter, and many of them have been 
shown to induce EAE, an experimental model of MS (Figure 2.3). 
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Figure 2.3  
MS and EAE auto-antigens in CNS white matter (modified from Hemmer et al., 2002). MBP, myelin 
basic protein; MOG, myelin oligodendrocyte glycoprotein; MAG, myelin associated glycoprotein; PLP, 
proteolipid protein; OA, oligodendrocyte antigens; NA, neuronal antigens. 
 
2.4.1 Myelin basic protein (MBP)  
 
MBP is one of the most abundant myelin proteins (approximately 30%–40%) and 
is probably the best-studied one in MS owing to its water solubility and ease of 
purification. It is found in both the central and the peripheral myelin sheath. MBP 
transcripts have also been demonstrated in peripheral lymphoid organs (Bruno et al., 
2002). Mammals have five MBP isoforms with an approximate molecular weight of 
14.0–21.5 KDa. These isoforms are produced by alternative splicing of 11 exons 
within the Golli-MBP locus (Seamons et al., 2003). MBP is positioned at the 
intracellular surface of myelin membranes, the so-called major dense line, which 
interacts with acidic lipid moieties to maintain the structure of compact myelin. MBP 
has been used extensively in MS as well as in EAE studies. Several mouse, rat 
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strains, guinea pigs, and nonhuman primates developed EAE after immunization 
with MBP-derived peptides (Wekerle et al., 1994). In humans, a large body of 
evidence suggests that MBP is one of the main target autoantigens. Several 
immunodominant epitopes have been described together with MS-associated class 
II alleles. Moreover, TCR transgenic mice have been generated for the 
immunodominant MBP, and they also developed spontaneous EAE at various 
frequencies (see below; Goverman et al., 1993; Lafaille et al., 1994). 
2.4.2 Proteolipid protein (PLP)  
 
The membrane protein PLP is the most abundant CNS myelin protein (about 
50% of all myelin proteins). It is highly hydrophobic and highly conserved across all 
species. Two main transcripts have been described in mice: one encodes for the full-
length 276 amino acid (aa) isoform, the other for the DM-20 isoform lacking 35 
amino acids (Baumann and Pham-Dinh, 2001). The brain and spinal cord mainly 
express full-length PLP, whereas peripheral lymphoid organs express predominantly 
the DM-20 isoform (Bruno et al., 2002; Klein et al., 2000). This differential peripheral 
expression is relevant for one major encephalitogenic and immunodominant PLP 
139−154 peptide that is present in full-length PLP, but is absent in the DM-20 
isoform, and therefore is not available for thymic negative selection. Consequently, 
high frequencies of PLP 139−154-specific T cells have been observed even in naive 
unprimed animals (Kuchroo et al., 2002). Furthermore, PLP-specific TCR transgenic 
mice with a SJL/J genetic background spontaneously developed severe EAE 
(Waldner et al., 2000). 
2.4.3 Myelin oligodendrocyte glycoprotein (MOG) 
 
MOG was originally identified to be a target of antibody-mediated demyelination in 
a guinea pig model of EAE (Linington and Lassmann, 1987; Lebar et al., 1986). It is 
a 218 aa glycosylated transmembrane protein and a member of the Ig superfamily. 
Quantitatively, it is a minor constituent of the CNS myelin sheath, where it accounts 
for approximately 0.05% of all myelin proteins. It is expressed only in the CNS and is 
highly conserved between different species (Johns and Bernard, 1999). MOG is 
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expressed late during the formation of the compact myelin sheath (Slavin et al., 
1997). The function of MOG is still not known, since MOG knockout (KO) mice 
develop in a phenotypically normal way (Delarasse et al., 2003; Linares et al., 2003). 
The topology of MOG indicates that it has two membrane-associated regions, 
where the C-terminal domain is associated with rather than spans the membrane. 
Recent structural investigation confirmed these observations (Breithaupt et al., 2003; 
Clements et al., 2003). Table 2.1 summarizes the biochemical properties of MOG. 
 
Table 2.1 
Properties of MOG (Johns and Bernard, 1999; von Budingen et al., 2001) 
1. CNS myelin specific integral membrane glycoprotein present on the surface 
of oligodendrocytes and on the outer lamellae of the myelin sheath 
2. Expression parallels with myelination 
3. Surface marker of oligodendrocyte maturation 
4. Molecular size of 28 kDa on SDS-PAGE 
5. Glycosylated in native form and N-glycosylation at position 31 
6. Highly conserved in different species 
7. Maps to the MHC region in the mouse, rat, and human  
 
MOG can be differentiated from other myelin autoantigens, since it is accessible 
to both T cell and antibody-mediated damage owing to its location on the outermost 
lamellae of the myelin sheath. Due to this accessibility, several lines of evidence 
suggest that MOG plays an important role in the pathogenesis of MS. Although it is a 
minor glycoprotein of the CNS myelin sheath, significant T cell responses and anti-
MOG antibodies have been identified in MS patients. Furthermore, anti-MOG 
antibodies were detected in the CSF of some patients (Xiao et al., 1991), and they 
were specifically bound to the disintegrating myelin around axons in lesions of acute 
MS patients (Genain et al., 1999). Anti-MOG antibodies together with 
encephalitogenic T cells produce demyelination similar to MS in a marmoset model 
of EAE (Genain et al., 1995), and extensive demyelination was observed in 
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immunized rodents after injection of anti-MOG monoclonal antibody (Schluesener et 
al., 1987).  
The mechanisms by which MOG-specific antibodies induce demyelination are not 
known. Obviously, the ability to fix complement is attributed to the demyelination 
induced by MOG/anti-MOG complex (Piddlesden et al., 1993). Other mechanisms 
including antibody-dependent cell cytotoxicity (ADCC) and the direct role of anti-
MOG antibody-induced demyelination have also been proposed. Recently, it was 
shown that anti-MOG antibody-induced cross-linking of oligodendrocytes leads to 
the repartitioning of MOG into lipid rafts, specialized plasma membrane 
microdomains rich in cholesterol and glycosphingolipids. These rafts serve as a 
platform for the initiation of signal transduction by favoring specific protein-protein 
interactions. Further MOG antibody alters the phosphorylation states of specific 
proteins, increases Ca2+ influx, and activates MAPK, Akt pathways, resulting in 
dramatic changes in oligodendrocyte cell processes (Marta et al., 2005a; Marta et 
al., 2003). All these data clearly indicate that anti-MOG antibody plays a direct role in 
the induction of demyelination in addition to mediating damage to the immune 
complex. Moreover, pathogenic and non-pathogenic antibodies can be distinguished 
by their ability to bind conformational epitopes of MOG (Bourquin et al., 2003; Marta 
et al., 2005b).  
2.4.4 Other myelin and non-myelin antigens 
 
In addition to the antigens described above, several other myelin and non-myelin 
antigens have also been implicated in MS pathogenesis. These include MAG, 
CNPase, oligodendrocyte specific protein (OSP), myelin-associated oligodendrocytic 
basic protein (MOBP), α, β-crystallin, and s100β. 
MAG is located at the inner surface of the myelin sheath opposite to the axon 
surface, while MOBP, like MBP, is located at the major dense line of compact 
myelin. Both MAG 596−612 and MAG 609−62 peptides (Andersson et al., 2002; 
Morris-Downes et al., 2002) as well as MOBP 37–60 peptide (Holz et al., 2000) have 
been found to induce EAE in animals. MAG and MOBP-specific antibodies have also 
been found in the CSF of MS patients. 
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OSP, the third most abundant myelin protein (7%), is expressed at the tight 
junctions of the CNS and testis. Several OSP peptides were shown to induce EAE in 
SJL/J mice. Occasionally, OSP-specific antibodies are also found in the CSF of RR-
MS patients (Bronstein et al., 1997). 
2.5 Immune responses in the pathogenesis of MS 
MS is considered a Th1-mediated disease. This view is mainly based on the 
cellular composition of brain lesions and CSF as well as the data from EAE models. 
EAE can be induced either by injecting myelin components or by transferring Th1 
cell lines specific for the myelin proteins into susceptible animals. The transfer of 
antibodies does not induce EAE. This concept may, however, be too simplistic to 
cover the complete spectrum of multiple sclerosis pathology. Recently, antibodies 
(Cross et al., 2001) and CD8+ T cells (Babbe et al., 2000; Friese and Fugger, 2005) 
have been implicated in the pathogenesis of MS. Figure 2.4 shows the current view 
on the pathogenesis of MS. 
Irrespective of the causative agent, two critical steps are required for the 
autoreactive lymphocytes to damage the CNS. First, the myelin antigen-reactive 
lymphocytes must be activated in the periphery to enter through the BBB. This 
specific migratory pattern and functional changes of autoreactive T cells have been 
observed in an experimental model of the adoptive transfer of EAE. The model 
clearly indicates that the activation of T cells is required for migration across the BBB 
(Flugel et al., 2001). Second, the MHC class II and co-stimulatory molecules must 
be upregulated by the pro-inflammatory milieu in the CNS. Normally the CNS is an 
immune-privileged organ due to its low expression of MHC molecules and the 
absence of professional APCs. This is an important factor in the outcome of CNS 
damage, since local reactivation of the autoreactive T cells requires efficient antigen 
presentation by the APCs.  
In a genetically susceptible individual, T (CD4+ and CD8+) and B cells might be 
primed in the peripheral lymphoid organs either by endogenous antigen released 
from the CNS or by cross-reactive antigen from microbes. Dendritic cells, 
macrophages, and antigen-specific B cells are potent APCs, which efficiently 
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stimulate T cell responses. Underlying defects in the immunoregulatory mechanisms 
such as decreased numbers of regulatory cells (Tregs) in some individuals allow 
further activation of the autoreactive cells. B cells could also be activated by the 
antigen. When enhanced by cytokines released by T cells, the activated B cells 
might eventually differentiate into antibody-producing plasma cells.  
 
 
 
Figure 2.4  
Current concepts of immunopathogenesis of MS. (For explanation please see the text)  
 
After initial priming in the periphery, both activated T and B cells undergo clonal 
expansion and migrate across the BBB to reach the CNS. In the CNS, T cells are 
reactivated by the local antigen presenting cells such as activated microglia or CNS 
infiltrated macrophages. CD8+ T cells recognize the myelin antigens presented by 
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MHC I molecules and can directly damage the cells expressing the antigens. 
Reactivation of autoreactive CD4+ T cells by specific antigens leads to the secretion 
of proinflammatory cytokines, which further attract other immune cells like 
macrophages. Macrophages contribute to the inflammation by releasing several 
inflammatory mediators as well as by initiating phagocyotosis of the myelin sheath. 
CNS infiltrated B cells re-encounter the antigen, mature to antibody producing 
plasma cells, and secrete large amounts of antigen-specific Ig. These antibodies 
damage the myelin sheath either by complement-mediated damage or by direct 
activation of the downstream signaling mechanisms (Hemmer et al., 2002; Hafler, 
2004). 
2.6 Major players in MS 
2.6.1 CD4+ T Cells 
 
Since Rivers showed  that the injection of spinal cord or brain homogenates into 
healthy primates caused a disease similar to MS (Rivers et al., 1933), many animal 
models have been developed by immunization with purified myelin antigens together 
with adjuvant (Gold et al., 2000). In addition, the transfer of CD4+ encephalitogenic T 
cell lines has also been shown to induce disease (Wekerle et al., 1994; Ben-Nun et 
al., 1981). These animal models showed that the CD4+ T cells are the main players 
in EAE. This view, however, is probably oversimplified, as these models did not 
reproduce MS in all its clinical and structural aspects.  
Nevertheless, MS favors CD4+ autoreactive T cells as a central factor in the 
autoimmune pathogenesis. CD4+ T cells are the major component in MS lesions and 
in CSF-infiltrating inflammatory cells in MS. Furthermore, linkage studies have 
shown that a substantial degree of genetic risk is conferred by HLA-DR and HLA-DQ 
molecules. Indeed, “humanized” transgenic mice expressing either MS associated 
HLA-DR or -DQ molecules are susceptible to EAE (Kawamura et al., 2000), and 
mice expressing both MS-associated HLA-DR molecules and MS patient–derived 
MBP-specific TCR develop spontaneous or induced EAE (Madsen et al., 1999). 
Many investigators have reported various frequencies of myelin antigen specific T 
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cells present in the peripheral blood mononuclear cells (PBMCs) of MS patients as 
well as healthy people (Sospedra and Martin, 2005).  
2.6.2 CD8+ T Cells 
 
The role of CD8+ T cells in the pathogenesis of MS was ignored for a long time. 
One reason for this was that the CNS was considered an immune-privileged organ 
and protected from T cell-mediated damage, partly by the reduced expression of 
MHC class I molecules. In addition, CD8+ T cells are difficult to handle in vitro. 
However, several lines of evidence support the direct or indirect role of CD8+ T cells 
in MS (Friese and Fugger, 2005). Pronounced oligoclonal expansions of CD8+ 
memory T cells have been found in the CSF (Jacobsen et al., 2002), MS brain tissue 
and in blood (Babbe et al., 2000). In addition, many HLA class I–restricted myelin 
epitopes have been described for several myelin proteins. At least for some of them 
CD8+ T cell clones have been isolated from the patients (Tsuchida et al., 1994). 
Further, MBP-specific CD8+ T cell response has been shown to be increased in MS 
patients (Zang et al., 2004). Finally, MOG and MBP specific cytotoxic T cells are 
shown to induce EAE in animal models (Huseby et al., 2001a; Sun et al., 2001). 
2.6.3 B cells and antibodies  
 
There is much evidence to implicate B cells and antibodies in the pathogenesis of 
MS. The observation that oligoclonal Igs are present in the CSF of MS patients and 
are produced intrathecally, indirectly suggested a role for B cells and antibodies 
(Walsh and Tourtellotte, 1986; Walsh et al., 1985). However, no pathological role for 
CSF antibodies was demonstrated with certainty. Myelin-specific antibodies have 
been found in chronic MS plaques as well as in active MS lesions (Genain et al., 
1999). Further, a recent pathological study has also shown that type II lesions are 
mainly antibody-mediated (Lucchinetti et al., 2000).  
Many investigators have observed the presence of specific antibodies for MOG, 
MBP, PLP, MAG, CNPase, and several other myelin antigens in MS patients (Cross 
et al., 2001; Sospedra and Martin, 2005). Although it is unlikely that all these 
antibodies have a direct functional role in the pathogenesis in MS, MOG-specific (but 
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not anti-MBP or anti-PLP) antibodies were shown in experimental models to 
accelerate EAE (Genain et al., 1995; Schluesener et al., 1987; Storch et al., 1998). 
An MOG-specific antibody expressing transgenic mice developed EAE with earlier 
onset when immunized with myelin antigens (Litzenburger et al., 1998). In addition, 
resistance to recombinant MOG-induced EAE in B cell deficient mice compared to 
MOG 35-55-induced EAE suggested a critical role for B cells (Lyons et al., 1999). 
In principle, both B cells and antibodies can contribute to MS disease 
pathogenesis in several ways. (a) B cells act as APCs to capture and present the 
autoantigen(s) to autoreactive T cells. (b) B cells might provide co-stimulation to 
autoreactive T cells. (c) They might recruit autoreactive T cells to the CNS by 
binding Igs. (d) B cells might also be responsible for the opsonization of myelin for 
phagocytosis and destruction of myelin within plaques. e) B cells can also secrete 
cytokines to create an inflammatory milieu.  
2.7 Animal models of multiple sclerosis 
 
Animal models have been used extensively in biomedical research. They are 
invaluable for investigating disease mechanisms. Prompted by the unexpected 
observation that immunization of humans against viral diseases such as rabies with 
CNS contaminated vaccines triggered paralytic CNS disease, Thomas Rivers 
injected brain extracts from rabbits into monkeys and showed a similar CNS disease 
(Rivers et al., 1933). Since then scientists have investigated the demyelinating 
potential of several myelin antigens together with adjuvants (MBP, PLP, MOG, and 
MAG; see Figure 2.3). These models are collectively called EAE.  
EAE can be induced in several rodent strains as well as in primates, either by 
active immunization or passive transfer of T cells. The immunization of susceptible 
animals with complete Freund’s adjuvant (CFA) containing heat-killed 
Mycobacterium tuberculosis was shown to produce encephalomyelitis and is known 
as active EAE (Gold et al., 2000; t Hart et al., 2004). Later, Paterson et al. showed 
that the adoptive transfer of lymphocytes obtained from sensitized animals caused 
clinical symptoms of EAE in naïve recipients (termed passive EAE induction; 
Paterson, 1960). The classic EAE induced by immunization with myelin antigens in 
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CFA or adoptive transfer of encephalitogenic T cells in the Lewis rat results in a 
characteristic ascending paralysis, which starts with a flaccid tail, hind-limb 
weakness, leading to paralysis of the hind limbs, and occasionally ending with 
complete hind and forelimb paralysis. 
EAE models are heterogeneous in nature. Every model differs from all others by 
several aspects that include sensitivity, clinical course, and pathology. The 
sensitivity and clinical course of the disease depends on several factors such as 
age, sex, antigen, dose, route of administration, and species. Several species and 
strains including rats, mice, marmosets, and monkeys have been used to induce 
EAE. All differ in their clinical course as well as sensitivity to the antigen. The clinical 
course of EAE models is classified as acute, hyperacute, chronic-progressive, or 
relapsing–remitting. The differences between species and strains can partly be 
explained by the genetic variations in the MHC gene as well as other genes known 
to modulate the immune responses. For example, the response to a particular 
encephalitogenic epitope is dependent on the population of TCR and MHC class II 
molecules (Swanborg, 1995). Consequently, each animal species might offer an 
advantage for studying a particular aspect of the disease but the evaluation of novel 
therapies should be validated in several models (Steinman, 1999).  
2.7.1 Mouse models 
 
The mouse model offers several unique advantages over most other EAE models: 
the extensive knowledge accumulated in mouse genetics; the availability of 
molecular and immunological reagents; and the availability of transgenic and 
knockout strains, all of which make the mouse a first-choice model organism. 
Depending on the mouse strain analyzed, either a monophasic chronic-progressive 
or the relapsing–remitting form of MS can be observed. Clinical disease in mice is 
paralleled by histopathological changes of severe inflammation in the CNS; in some 
mouse models, this is accompanied by demyelination. However, the relative 
resistance of other mouse strains to EAE induction, the variability in disease 
incidence and kinetics, and the need for strong adjuvants, including mycobacteria 
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and pertussis toxin, make it difficult to study certain aspects of the pathogenesis. For 
example, adoptive transfer of EAE is more difficult in mice than in Lewis rats. 
 2.7.1.1 Induced models 
 
Most of the active EAE induction protocols require CFA as an adjuvant. It 
facilitates the gradual and constant release of antigen into the draining lymph nodes, 
thus delaying the destruction of the antigen and increasing its dispersion. The 
mycobacteria in CFA amplify the immune response by stimulating the innate 
immune system. This causes a strong inflammatory response that leads to lymph 
node hyperplasia and augments the T cell responses. Pertussis toxin is often used 
to induce EAE in mice (Linthicum and Frelinger, 1982). It is thought to support the 
induction of EAE by breaking down T cell tolerance (Waldner et al., 2004), 
penetrating the BBB, and activating TLR4 (Racke et al., 2005). 
Passive EAE induction by means of the transfer of encephalitogenic T cell clones 
or lines obtained from immunized animals and stimulated in vitro by the autoantigen 
offers the advantage of eliminating the use of additional adjuvant, which results in a 
strong artificial inflammatory condition. Under such conditions, EAE develops more 
quickly and is less variable, allowing study of the effector phase of the disease 
independently of the mechanisms involved in the induction phase (Wekerle et al., 
1994).  
However, induced models have several drawbacks. Not only are they artificial, but 
they also do not reflect the true pathogenic mechanisms of MS. While MS pathology 
(described in section 2.5) is complex and involves pronounced demyelination and 
cellular infiltration, induced mouse models are often too simple. Extensive 
demyelination and a topology of the lesions similar to that in human MS are often not 
reproduced in the experimental EAE models. Moreover, the potential role of 
antibodies and B cells might also be underestimated in the classic models of Th1-
prone EAE. Finally, experimental difficulties in the induction and generation of T cell 
lines from some strains limit their usefulness for the study of pathogenic 
mechanisms.  
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2.7.1.2 Transgenic models 
 
Transgenic models have been instrumental in the study of the pathogenesis of 
MS. They offer selective advantages over induced models for the study of 
pathogenic mechanisms and the evaluation of novel therapeutic compounds. HLA II 
transgenic mice, pathogenic TCR or BCR (B cell receptor) transgenic mice knock-in, 
and knock-out mice were developed and used in several studies. Human HLA class 
II or rodent MHC class II restricted TCR transgenic mice were derived from T cell 
clones isolated either from MS patients or from sensitized animals. This procedure is 
mainly based on the view that MS is mediated by Th1 cells. 
 
HLA transgenics 
 
HLA transgenic mice express the susceptible MHC II genes from patients and 
interact better with human TCR to mimic the human disease. Transgenic mice that 
express the DRB1*1501 allele, as well as an MS patient-derived TCR specific for the 
DRB1*1501-MBP (85–99) complex, and the human CD4 co-receptor have been 
generated. About 4% of these mice developed spontaneous EAE. The incidence 
was increased in recombinase-activating gene (RAG)-deficient background. After 
immunization, they developed relapsing-remitting EAE as in MS, thus supporting the 
involvement of the DRB1*1501-restricted MBP epitope in the pathogenesis of MS 
(Madsen et al., 1999). Several other HLA transgenic mice that express HLA-
DRB1*0101 (recognizing MBP 139–154; Altmann et al., 1995), HLA-DRB1*0401 
(recognizing MBP 87–106; Ito et al., 1996), and  HLA-DRB1*1502 (recognizing PLP 
95–116; Kawamura et al., 2000) have also been used. 
 
TCR and BCR transgenic models 
 
The earliest TCR transgenic models that recognize I-Au restricted MBP Ac1-11 
peptide were developed (Goverman et al., 1993; Lafaille et al., 1994). Like HLA II 
transgenic mice, TCR transgenic mice derived from human pathogenic T cell clones 
were also generated (Madsen et al., 1999; Ellmerich et al., 2004). They were used to 
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study disease-related epitope spreading and other aspects of pathogenesis. During 
the last decade, several TCR transgenic models have been created in different 
strains and for different myelin antigenic peptides (Table 2.2). 
Studies of TCR transgenic mice have provided useful insights into the complex 
pathogenic mechanisms. For example, the contribution of environmental triggers to 
induce EAE was studied in MBP-specific TCR transgenic mice, approximately 14 - 
44% of which developed spontaneous EAE under conventional housing conditions 
but not in specific pathogen-free (SPF) conditions (Goverman et al., 1993). These 
studies suggested possible environmental trigger(s) for EAE, but a definite candidate 
pathogen was not established. 
 
Table 2.2 TCR transgenic models of multiple sclerosis (Modified from Lafaille, 2004). 
 
 
In another model of MBP TCR mice, 100% of the transgenic mice developed EAE 
in a RAG-deficient background, in which all T cells bear the pathogenic TCR, since 
rearrangements of endogenous TCR are not possible (Lafaille et al., 1994). This 
study suggested the importance of regulatory lymphocytes in dampening EAE. 
Indeed, the transfer of polyclonal T cells completely suppressed spontaneous EAE 
(Olivares-Villagomez et al., 1998). PLP 139-151 specific TCR (obtained from both 
encephalitogenic and non-encephalitogenic clones) transgenic mice with a 
susceptible SJL/J genetic background developed severe spontaneous EAE but 
remained healthy with a resistant B10.S background (Waldner et al., 2000). This 
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resistance is attributed to the lower activation state and poor T cell stimulatory 
activity of APCs (Waldner et al., 2004). In addition, CD4+CD25+ regulatory cells 
(Tregs), which also contribute to the resistance and depletion of Tregs, restored their 
susceptibility to EAE induction by PLP 139-151 immunization (Reddy et al., 2005). 
Recently, an MOG 35-55-specific TCR transgenic mouse was developed with a 
C57BL/6 genetic background. Isolated optic neuritis (>30%) and low-grade EAE 
(4%) were observed in these mice (Bettelli et al., 2003). In addition to the CD4 TCR 
transgenic models, Goverman & colleagues developed the first TCR transgenic mice 
expressing MHC class I restricted TCR for MBP peptide (Perchellet et al., 2004) 
 Besides T cells, B cells might also play an important role in MS. B cells and 
antibodies have been shown to be essential for MS and EAE in several studies 
(Cross et al., 2001). Only one myelin antigen-specific BCR knock-in mouse model 
has been developed so far. It expresses a rearranged heavy chain from an MOG- 
specific antibody (8.18-C5). In contrast to TCR transgenic models, these mice never 
showed any sign of spontaneous CNS autoimmunity, but enhanced kinetics of 
diseased induction was observed when they were immunized with myelin antigens 
other than MOG (Litzenburger et al., 1998).  
2.7.1.3 Novel model of T and B cell interaction 
 
Undoubtedly, the above-described models (either induced or transgenic models) 
have contributed to our understanding of several facets of MS pathogenesis and 
allowed evaluation of therapeutic interventions. However, most of these animal 
models focus on either pathogenic T cells or B cells alone. Moreover, none of them 
reproduce the human disease in all its clinical and pathological aspects. Most 
importantly, none has shown that the interaction of pathogenic T and B cells 
precipitates autoimmunity.  
To understand the interaction between antigen-specific T and B cells and their 
contribution to EAE, the present study used TCR and BCR transgenic mice available 
with the same genetic background. The TCR transgenic mice (TCRMOG) used in the 
current study recognize the MOG 35-55 peptide in the context of I-Ab and express 
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the rearranged TCR α and β chain from the pathogenic T cell clone obtained from 
immunized animals (Bettelli et al., 2003). A significant proportion (>30%) of the 
TCRMOG mice used in the present study was shown to develop a spontaneous optic 
neuritis without evidence of clinical or histological EAE, and approximately 4% of the 
mice developed spontaneous EAE at an older age. The BCR knock-in mice (IgHMOG) 
used in the present study were produced by gene targeting of the rearranged heavy 
chain VDJ sequence from the MOG-specific hybridoma 8.18-C5 to its natural locus 
(Litzenburger et al., 1998). This heavy chain recognizes the conformational epitope 
present in the extracellular portion of MOG. B cells in IgHMOG mice develop normally 
and secrete high titers of pathogenic antibodies in serum. While they never show 
autoimmunity, enhanced kinetics of EAE after immunization was observed. The 
present study used both TCRMOG and IgHMOG mice to produce double-transgenic 
mice which developed a spontaneous EAE, and restricted localization of the 
inflammatory demyelinating lesions in the CNS. 
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3. Objectives 
 
The role of CD4+ T cells in the pathogenesis of MS has been studied extensively in 
animal models. Increasing evidence implicates B cells. So far, however, no animal 
model has shown a clear role of autoantigen-specific B cells and their interaction 
with autoreactive T cells to cause CNS autoimmunity. 
 
This study was undertaken with the following objectives. 
1. To generate an EAE mouse model that involves myelin antigen MOG-specific B 
and T cells. 
2. To study the contribution of autoantigen-specific B cells in the pathogenesis of 
MS. 
3. To study the interaction of autoantigen-specific B and T cells in precipitating 
autoimmunity. 
4. To study the factors triggering CNS autoimmunity. 
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4. Materials and Methods 
4.1. Materials 
4.1.1 Antibodies 
Antibodies for ELISA 
 Specificity (anti-mouse)  Label Clone Antibody class Company 
IFNγ Biotin R4-6A2  Rat IgG1 Pharmingen 
IgG1 Biotin A85-1 Rat IgG1, κ Pharmingen 
IgG1a Biotin 10.9 Ms IgG2a, κ (mouse IgG2ab) 
Pharmingen 
IgG1b Biotin B68-2 Ms IgM, κ (mouse IgMa) Pharmingen 
IgG2a/2b Biotin R2-40 Rat IgG1, κ Pharmingen 
IgG2a/2ba Biotin 8.3 Ms IgG2a, κ (mouse IgG2ab) 
Pharmingen 
IgG3 Biotin R40-82 Rat IgG2a, κ Pharmingen 
IgM Biotin R6-60.2 Rat IgG2a, κ Pharmingen 
IgMa Biotin DS-1  Ms IgG1, κ (mouse IgG1b) 
Pharmingen 
IL2 Biotin JES6-5H4  Rat IgG2b Pharmingen 
IL4 Biotin BVD6-24G2 Rat IgG1 Pharmingen 
Detection 
antibodies 
IL5 Biotin TRFK4  Rat IgG2a Pharmingen 
IFNγ - AN-18  Rat IgG1, κ Pharmingen 
IgG1 - A85-3 Rat IgG2a, κ Pharmingen 
IgG2a  - R11-89 Rat IgG1, κ Pharmingen 
IgG2b - R9-91 Rat IgG1 Pharmingen 
IgG3 - R2-38 Rat IgG1, κ Pharmingen 
IgM - II/41 Rat IgG2a, κ Pharmingen 
IL2 - JES6-1A12  Rat IgG2a Pharmingen 
IL4 - BVD4-1D11 Rat IgG2b Pharmingen 
Capture 
antibodies 
IL5 - TRFK5  Rat IgG1 Pharmingen 
 
Isotype standards for Ig ELISA 
Name Clone Company 
Mouse IgG2a, κ isotype std (anti-TNP) G155-178  Pharmingen 
Mouse IgG1, λ isotype std S1-68.1  Pharmingen 
Mouse IgM, λ isotype std PMG1-146.1 Pharmingen 
Mouse IgG2b,κ isotype std MPC-11  Pharmingen 
Mouse IgG3, κ (anti-KLH) A112-3 Pharmingen 
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The recombinant cytokine standards for cytokine ELISA were purchased from 
Pharmingen. 
Antibodies (anti-mouse) for flow cytometry 
Specificity  Label Clone Antibody class Company 
CD11b PE M1/70 Rat IgG2b, κ Pharmingen 
CD154 PE MR1  Ar Ham IgG3, κ Pharmingen 
CD19 FITC 1D3 Rat IgG2a, κ Pharmingen 
CD19 PE 1D3 Rat IgG2a, κ Pharmingen 
CD25 FITC 7D4 Rat IgM, κ Pharmingen 
CD25 PE 3C7 Rat IgG2b, κ Pharmingen 
CD28 PE 37.51 Golden Syrian Hamster IgG eBioscience 
CD3e APC 145-2C11 Ar Ham IgG1, κ  Pharmingen 
CD3e FITC 145-2C11 Ar Ham IgG1, κ  Pharmingen 
CD4 PerCP RM4-5 Rat IgG2a, κ  Pharmingen 
CD44 FITC IM7 Rat IgG2b, κ Pharmingen 
CD44 PE IM7 Rat IgG2b, κ Pharmingen 
CD45R/B220 PerCP RA3-6B2 Rat IgG2a, κ Pharmingen 
CD62L Biotin MEL-14 Rat IgG2a, κ Pharmingen 
CD69 FITC H1.2F3  Ar Ham IgG1, λ3 Pharmingen 
CD69 PE H1.2F3  Ar Ham IgG1, λ3 Pharmingen 
CD80 Biotin  16-10A1  Ar Ham IgG2, κ Pharmingen 
CD86 Biotin GL1  Rat IgG2a, κ Pharmingen 
CD8a APC 53-6.7 Rat IgG2a, κ Pharmingen 
CDLA-4 PE UC10-4B9 Armenian Hamster IgG eBioscience 
ICOS PE 7E.17G9 Rat IgG2b,κ eBioscience 
ICOSL PE HK5.3 Rat IgG2a, κ eBioscience 
IFNγ FITC XMG1.2  Rat IgG1 Pharmingen 
IgMa Biotin DS-1 Ms IgG1, κ (mouse IgG1b) Pharmingen 
IgMa FITC DS-1 Ms IgG1, κ (mouse IgG1b) Pharmingen 
IgMa PE DS-1 Ms IgG1, κ (mouse IgG1b) Pharmingen 
IgMb FITC AF6-78 Ms IgG1, κ (mouse IgG1a) Pharmingen 
IgMb PE AF6-78 Ms IgG1, κ (mouse IgG1a) Pharmingen 
IL2 FITC S4B6 Rat IgG2a Pharmingen 
IL4 FITC BVD4-1D11 Rat IgG2b Pharmingen 
MHC Class II  Biotin 2G9 Rat IgG2a, κ Pharmingen 
MOG Biotin 8.18-C5 Mouse IgG1 In house 
PD-1 PE RMP1-30 Rat IgG2b, κ eBioscience 
PDL-1 PE MIH5 Rat IgG2a, λ eBioscience 
PDL-2 FITC 122 Rat IgG2a, κ eBioscience 
TNFα FITC MP6-XT22  Rat IgG1 Pharmingen 
Vα 3.2 TCR FITC RR3-16 Rat IgG2b, κ Pharmingen 
Vβ 11 TCR PE RR3-15 Rat IgG2b, κ Pharmingen 
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4.1.2 Buffers and reagents 
Tail digestion buffer 
100 mM Tris HCl pH 8.5 
5 mM EDTA 
0.5% Tween 20 
1 mg/ml Proteinase K (added before digestion) 
FACS buffers 
a. Staining buffer 
PBS + 1% bovine serum albumin (BSA) + 0.1% sodium azide  
b. Saponin buffer 
0.1% saponin in PBS 
c. PFA/saponin buffer 
4% paraformaldehyde (PFA) + 0.1% saponin in PBS 
Cell culture medium  
RPMI 1640 or DMEM medium with sodium bicarbonate (Gibco) 
1% MEM non essential amino acids (100 X; Gibco) 
1% sodium pyruvate (100 mM; Gibco) 
1% Pen-strep (Penicillin G 10,000 units/ml; streptomycin 10,000 μg/ml; 
Gibco) 
1% glutamine solution (Gibco, 200 mM)  
400 µl/ L β-mercaptoethanol (10 µl/10 ml media, pre-prepared) 
10% heat-inactivated fetal calf serum (FCS) 
Red blood cells (RBC) lysis buffer 
 0.83% ammonium chloride in PBS 
Heparin solution 
5000 units heparin (Sigma) in PBS  
CFSE stock solution 
 5 mM in dimethyl sulfoxide (DMSO) 
Isotonic percoll solution 
 9 parts (v/v) of percoll + 1 part (v/v) of 1.5 M sodium chloride 
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Neutralization buffer (for antibody purification) 
1 M Tris HCl pH 9.0 
Elution buffer (for antibody purification) 
0.1 M glycine HCl pH 2.7 
Binding buffer (for antibody purification) 
20 mM sodium phosphate pH 7.0  
LB medium 
Peptone      10g 
Yeast extract      5g 
NaCl         5g 
Distilled water up to  1000 ml 
Elution buffer (for MOG purification) 
6 M guanidium chloride + 0.5 M imidazole  
Equilibration buffer (for MOG purification) 
6 M guanidium chloride pH 8.0 
Wash buffer (for MOG purification) 
6 M guanidium chloride + 40 mM imidazole  
Ni-NTA column regeneration buffer 
1 % EDTA + 0.05 % Tween-20 
Solubilization buffer (for MOG purification) 
6 M guanidium chloride + 20 mM β-mercaptoethanol 
Sonication buffer (for MOG purification) 
2 × PBS 
Lysis buffer (for MOG purification) 
Sonication buffer + 0.5 % LDAO (N, N-dimethyldodecylamine-N-oxide, Fluka) 
+ lysozyme 
Wash buffer (ELISA) 
PBS + 0.05 % Tween 20 
Assay diluent (ELISA) 
PBS + 10% FCS 
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4.1.3 Primers 
 
Primers for gene expression analysis 
      Label 
Primer name Gene Oligo sequence (5' -> 3') 5' 3' 
mGAPDH-sense #1 GAPDH TCA CCA CCA TGG AGA AGG C - - 
mGAPDH-AS #2 GAPDH GCT AAG CAG TTG GTG GTG CA - - 
mGAPDH-Probe #3 GAPDH ATG CCC CCA TGT TTG TGA TGG GTG T FAM TAMRA
mFoxP3 sense #1 FoxP3 AGG AGA AGC TGG GAG CTA TGC - - 
mFoxP3 AS #2 FoxP3 TGG CTA CGA TGC AGC AAG AG - - 
mFoxP3 Probe #3 FoxP3 AAG GCT CCA TCT GTG GCC TCA ATG GA FAM TAMRA
mIL-5 sense #1 IL-5 CCG CTC ACC GAG CTC TGT T - - 
mIL-5 AS #2 IL-5 AGA TTT CTC CAA TGC ATA GCT GG - - 
mIL-5 Probe #3 IL-5 CAG GAA GCC TCA TCG TCT CAT TGC 
TTG T 
FAM TAMRA
mIL-10 sense IL-10 CAGAGAAGCATGGCCCAGAA - - 
mIL-10 AS IL-10 TGCTCCACTGCCTTGCTCTT - - 
mIL-10 Probe IL-10 TGAGGCGCTGTCATCGATTTCTCCC FAM TAMRA
mEotaxin sense Eotaxin AGAGCTCCACAGCTTCTATT - - 
mEotaxin AS Eotaxin CTTACTGGTCATGATAAAGCAGCAG - - 
mEotaxin Probe Eotaxin ACGGTCACTTCCTTCACCTCCCAGG FAM TAMRA
mIFNγ sense IFNγ TCAAGTGGCATAGATGTGGAAGAA - - 
mIFNγ AS IFNγ TGGCTCTGCAGGATTTTCATG - - 
mIFNγ Probe IFNγ TCACCATCCTTTTGCCAGTTCCTCCAG FAM TAMRA
mTNFα sense TNFα CATCTTCTCAAAATTCGAGTGACAA - - 
mTNFα AS TNFα TGGGAGTAGACAAGGTACAACCC - - 
mTNFα probe TNFα CACGTCGTAGCAAACCACCAAGTGGA FAM TAMRA
mIL-4 sense IL-4 ACAGGAGAAGGGACGCCAT - - 
mIL-4 AS IL-4 GAAGCCCTACAGACGAGCTCA - - 
mIL-4 probe IL-4 TCCTCACAGCAACGAAGAACACCACA FAM TAMRA
mIL-13 sense IL-13 GGAGCTGAGCAACATCACACA - - 
mIL-13 AS IL-13 GGTCCTGTAGATGGCATTGCA - - 
mIL-13 probe IL-13 CGGGTTCTGTGTAGCCCTGGATTCC FAM TAMRA
mIP-10 sense IP-10 GCCGTCATTTTCTGCCTCAT - - 
mIP-10 AS IP-10 GCTTCCCTATGGCCCTCATT - - 
mIP-10 probe IP-10 TCTCGCAAGGACGGTCCGCTG FAM TAMRA
 
IFN-γ, TNFα, IL-4, IL-13 and IP-10 Taqman probes were synthesized as described 
(Giulietti et al., 2001). 
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Primers for genotyping transgenic mice 
   Label 
Primer name Gene Oligo sequence (5' -> 3') 5' 3' 
8.18C5-sense #1 anti-MOG IgH (8.18C5) 
TGA GGA CTC TGC CGT CTA 
TTA CTG T 
- - 
8.18C5-AS #2 anti-MOG IgH (8.18C5) 
GGA GAC TGT GAG AGT GGT 
GCC T 
- - 
8.18C5-Probe #3 anti-MOG IgH (8.18C5) 
CCA GTA TGG CAT GTT TAC 
CAT CGT ATT ACC AGT T 
FAM TAMRA 
mIgH-sense #1 Ig heavy chain ATT GGT CCC TGA CTC AAG 
AGA TG 
- - 
mIgH-AS #2 Ig heavy chain TGG TGC TCC GCT TAG TCA AA - - 
mIgH-Probe #3 Ig heavy chain CCT TGC ACC AGT CAG AGA 
CCA CAG GG 
FAM TAMRA 
Va3.2-2D2-M Valpha 3.2 TCR 
CCC GGG CAA GGC TCA GCC 
ATG CTC CTG 
- - 
Ja18-2D2-M Valpha 3.2 TCR 
GCG GCC GCA ATT CCC AGA 
GAC ATC CCT CC 
- - 
mRAG-2 sense #1 RAG2 GGG AGG ACA CTC ACT TGC 
CAG TA 
- - 
mRAG-2 AS #2 RAG2 AGT CAG GAG TCT CCA TCT 
CAC TGA 
- - 
Neo-2 #3 
Neomycin 
resistance 
gene 
AGG TGA GAT GAC AGG AGA 
TC 
- - 
nlacZ  lacZ GATGGGCGCATCGTAACCGTGC - - 
mMOG-sense #1 MOG AGG AAG GGA CAT GCA GCC 
GGA G 
- - 
mMOG-AS #2 MOG CTG CAT AGC TGC ATG ACA 
ACT G 
- - 
oIMR1825 Ovalbumin GCT GCT GCA CAG ACC TAC T - - 
oIMR1826 Ovalbumin CAG CTC ACC TAA CAC GAG GA  - - 
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4. 2 Methods 
4.2.1 Animals  
 
All animals used in this study had a C57BL/6 genetic background and were 
maintained in the conventional and SPF animal facilities of Max-Planck Institute of 
Neurobiology, Martinsried, Germany. TCRMOG (2D2; Bettelli et al., 2003) was 
generously provided by Drs. Estelle Bettelli and Vijay K. Kuchroo (Harvard Medical 
School, Boston, MS, USA). The transgenic IgHMOG knock-in (Th) mouse was 
described previously (Litzenburger et al., 1998). MOG knock-out mice (Delarasse et 
al., 2003) was a kind gift from Dr. Danielle Pham-Dinh (INSERM, Unité 546, Paris, 
France). Ovalbumin-specific TCR transgenic (OT-II) mice were purchased from the 
Jackson Laboratories, and RAG2-deficient mice were obtained from Max-Planck 
Institute of Immunobiology, Freiburg, Germany. Wild-type (WT) C57BL/6 mice were 
obtained from the animal facility of the Max-Planck Institute of Biochemistry, 
Martinsried, Germany.  
4.2.2 Genotyping 
 
Transgenic animals were genotyped by either conventional polymerase chain 
reaction (PCR) or real-time PCR of genomic DNA extracted from a piece of tail. A 
small piece of tail was clipped after weaning and incubated overnight in tail digestion 
buffer containing proteinase K (Roche) at 55°C. Then 500 µl of 
phenol/chloroform/isoamyl alcohol (Roth) were added and mixed well. After spinning 
at a maximum speed for 5 min, an aqueous layer was transferred into a fresh test 
tube. DNA was precipitated with 1 ml of ethanol for 5 min at maximum speed and 
washed with 70% ethanol. Precipitated DNA was dissolved in 400 µl of 10 mM Tris 
buffer at pH 8.0 and stored at -20°C. 
The typical PCR mixture consists of 
   Tail genomic DNA     1 µl 
10X buffer        2.5 µl 
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10 µM Sense primer    0.5 µl 
   10 µM Anti-sense primer  0.5 µl 
   10 mM dNTPs      0.5 µl 
   Taq polymerase (5 units/μl) 0.1 µl 
   H2O up to        25 µl  
The typical real-time PCR reaction consists of 
   Tail genomic DNA     0.5 µl 
10 µM Sense primer    0.5 µl 
   10 µM Anti-sense primer  0.5 µl 
   10 µM probe       0.5 µl 
   ROX 1:50        0.5 µl 
   Thermomix       10 µl 
   H2O up to        20 µl  
Taq polymerase was purchased either from Roche or Invitrogen, and real-time PCR 
mix was obtained from ABGene. 
4.2.3 Disease scoring  
 
All animals were examined at least once in 2 - 3 days for clinical signs of disease 
according to the classic EAE determination.  
0 : healthy animal 
1 : animal with a flaccid tail 
2 : animal with impaired righting reflex and/or gait 
3 : animal with one paralyzed hind leg 
4 : animal with both hind legs paralyzed 
5 : moribund or death after preceding clinical disease 
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4.2.4 Antigens 
 
MOG peptide 35-55 (MEVGWYRSPFSRVVHLYRNGK) was synthesized at 
BioTrend, Cologne, Germany. Recombinant soluble MOG protein (MOG 1 – 125) 
was purified from bacterial inclusion bodies (Amor et al., 1994). Expression plasmid- 
pQE-12 containing rat MOG 1-125 was grown in LB medium containing ampicillin 
(100 mg/ml; Sigma) and kanamycin (25 mg/ml; Sigma). The bacterial cultures were 
induced with isopropyl thiogalactoside (IPTG),and the cells were pelletted. The pellet 
was resuspended in lysis buffer with lysozyme and sonicated. Lysed samples were 
washed, suspended in solubilization buffer, and loaded onto the Ni-NTA column 
prepared with chelating sepharose and 1% NiCl2 (Amersham biosciences). The 
column was washed with wash buffer and eluted with elution buffer. Eluted MOG 
was dialyzed against 20 mM sodium acetate at pH 3.0. 
4.2.5 Immunization of animals 
 
Mice were injected (200 – 500 µl) subcutaneously (s.c.) at the tail base with an 
emulsion containing equal amounts of CFA (Difco) and 200 µg MOG 35-55 in PBS. 
CFA was supplemented with 5 mg/ml mycobacterium tuberculosis (strain H37Ra; 
Difco). Pertussis toxin (400 ng) was injected intraperitoneally (i.p.) on days 0 and 2 
following immunization. 
4.2.6 Serum collection 
 
Mice were bled by retro-orbital puncture, and the samples were allowed to clot 
overnight at 4°C. Serum was collected after spinning at 4°C/400 g for 10 min and 
stored at -20°C until further analysis. 
4.2.7 Isolation of CNS mononuclear cells  
 
The entire spinal cord was removed with a syringe from the animal and pressed 
through nylon mesh into RPMI medium (without serum). After centrifugation for 10 
min at 1200 rpm, it was suspended in 5 ml of RPMI and mixed with 2.16 ml of 
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isotonic percoll solution (Amersham Biosciences). The cell suspension was overlaid 
on 5 ml percoll and centrifuged at 20°C/1200 g for 20 min. The interface containing 
the mononuclear cells were collected and washed once with RPMI. 
4.2.8 Preparation of PBMCs 
 
 Blood was collected from the mice by retro-orbital puncture in a tube containing 
100 µl of heparin solution (5000 units/ml). RBC lysis buffer was added and incubated 
for 10 min on ice. Cells were spun down at 400 g/4°C for 10 min. The procedure was 
repeated once more and finally the cell pellet was suspended in PBS or processed 
as necessary. 
4.2.9 Cell purification 
 
Lymphocyte subpopulations were purified from the spleens of transgenic mice 
using B-cell or T-cell negative selection kits (Dynal Biotech, Norway). Single cell 
suspensions were prepared from the spleen of transgenic mice. RBC-lysed 
splenocytes were incubated with biotinylated antibody cocktail against cell surface 
antigens other than the cell population of interest. Dynabeads were mixed, and 
untouched CD4+ or B cells were isolated after placing the cell suspension in a 
magnet. The viability and purity of the cells were evaluated by FACS analysis. 
4.2.10 CFSE labeling of lymphocytes 
 
The cells (2 x 107) were incubated at 37°C/dark for 10 min with 1% FCS/PBS 
containing 5 µM CFSE (Molecular Probes). After extensive washing with cold PBS, 
cells were suspended in medium or PBS.  
4.2.11 In vitro proliferation assay 
  
The proliferation assay was performed in 96 well U bottom plates in triplicates. 
Splenocytes or 1:1 mixed purified cells (2 × 105 /well) were cultured with the 
indicated concentrations of rMOG or MOG 35-55 in a final volume of 200 µl RPMI 
medium. After 48 h incubation, cultures were pulsed with 3H-thymidine (specific 
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activity: 2 Ci/mmol; 1 µCi/well) (Amersham Biosciences). Samples were harvested 
after 16 h incubation, and the radioactivity was measured by the direct beta counter 
(MatrixTM 9600, Packard). 
4.2.12 Bone marrow chimera 
 
Bone marrow cells from Devic mice were collected from both femur and tibia. 
RBCs were lysed from pooled bone marrow cells by RBC lysis buffer. Cells were 
counted and suspended in serum-free RPMI or PBS. Subsequently 7-10 week (wk)-
old C57BL/6 females were sub-lethally irradiated at 1000 rad single dose just prior to 
injection. Then 10 × 106 RBC depleted bone marrow cells were injected 
intravenously (i.v) into each mouse and allowed to reconstitute. Serum antibody 
levels or levels of reconstitution were assessed after 4 wk by preparing PBMC or 
serum by retro-orbital bleeding.  
4.2.13 Adoptive transfer 
 
Transfer into TCRMOG mice 
 Splenocytes obtained from IgHMOG mice were depleted of RBCs and incubated 
with rMOG (1 µg/1 × 106) for 10 min at 37°C. Cells were washed extensively and 
suspended in PBS. Subsequently 20 × 106 cells were injected i.v. into recipient 
TCRMOG mice. Some mice simultaneously received i.p. 50 µg of LPS (E. coli 
serotype O111:B4). 
 
Transfer into RAG KO mice 
Splenocytes obtained from Devic (healthy), IgHMOG or TCRMOG were incubated in 
RBS lysis buffer to remove RBCs. Then they were washed and suspended in PBS. 
Subsequently 50 × 106 cells were injected i.v into each RAG KO mice. 
4.2.14 Histological analysis 
 
Animals were perfused transcardially with 4% paraformaldehyde (PFA) in PBS, 
stored in PFA for 24 h, and then washed twice with PBS. Brain and spinal cord 
tissue was dissected and in part embedded in paraffin or snap-frozen for 
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immunocytochemistry. Adjacent serial sections were stained with hematoxylin/eosin, 
luxol fast blue (LFB), or Bielschowsky silver impregnation. All histological analysis 
was performed by Prof. Hans Lassmann, University of Vienna, Austria. 
4.2.15 Immunohistochemistry 
 
Tissues isolated from the animals were frozen in Tissue Tek OCT compound on 
dry ice and stored at -20°C. Tissue sections (8 - 12 µm) were incubated with primary 
rat antibodies recognizing mouse CD4, CD11b, CD8α, IgM, CD19, or B220 (all 
obtained from BD Pharmingen). A secondary biotinylated anti-rat antibody, a 
streptavidin-horseradish peroxidase complex (both from Vector Laboratories), and 
diaminobenzidine (Zymed) allowed the cell type-specific detection of mononuclear 
cells. Slides were counterstained with Meyer’s hematoxylin and embedded in 
AquaMount (Fisher Scientific) prior to microscopic analysis.  
4.2.16 Flow cytometry 
Surface staining  
Single cell suspensions were incubated with fluorochrome-labeled antibodies 
diluted in FACS staining buffer on ice/dark for 20 min. Stained cells were washed 
twice and suspended in PBS. Samples were acquired in FACSCalibur (BD 
Biosciences). Biotinylated antibodies were visualized by Streptavidin-APC (BD 
Pharmingen).  
Intracellular staining  
 After surface staining, cells were suspended in PFA/saponin buffer for 10 min in 
the dark. After washing twice with saponin buffer, flurochorome-labeled anti-cytokine 
antibodies were added and incubated for another 30 min. Washed as above and 
suspended in PBS, samples were acquired in FACSCalibur.  
Data were analyzed with CellQuest (BD Biosciences) or WinMDI (Joe Trotter) 
software.  
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4.2.17 Hybridoma generation 
 
Splenocytes from the single transgenic mice were stimulated with 20 µg/ml LPS 
(E. coli serotype O111:B4) in vitro. After 3 days, cells were washed extensively to 
remove the serum. The hybridoma fusion partner cell line Sp2/0 growing in 
exponential phase was also harvested and washed. Splenocytes were mixed with 
Sp2/0 cells (5:1), and 0.5 ml of 50% polyethylene glycol was added slowly with 
gentle mixing. Cells were kept at 37°C for 1 min, diluted with serum-free media, and 
spun down and plated in 96-well plates at 1-2 × 106 cells/ml in Hybrimax® HAT 
(Sigma) containing DMEM/20% FCS. Seven days later medium was replaced with 
Hybrimax® HT (Sigma) containing DMEM/20% FCS, and growing clones were 
expanded in DMEM/10% FCS. Sub-cloning was done by single-cell sorting with 
FACSVantage. 
4.2.18 Antibody purification 
 
 Antibody producing hybridomas were grown in cell stack (Corning) with 
DMEM/10% FCS. Culture supernatants were harvested and filtered to remove cell 
debris. Supernatants were applied to the Hitrap ® protein G column (Amersham 
Biosciences) and washed extensively with binding buffer to remove nonbinding 
proteins. Antibody was eluted from the column by the elution buffer and immediately 
neutralized in neutralization buffer. The antibody-containing fractions (measured by 
OD 280) were pooled and dialyzed against PBS overnight. 
4.2.19 Enzyme linked immunosorbent assay (ELISA) 
Cytokine ELISA  
 
Splenocytes (2 × 105 cells/well) were either unstimulated or stimulated with rMOG  
in 96-well “U” bottom plates for 3 days, and supernatants were collected and frozen 
at -20°C. ELISA plates (Nunc) were coated with 100 µl of capture antibodies (1 µg/ml 
in 0.1 M NaHCO3 pH 9.0) for overnight at 4°C. Plates were washed with wash buffer 
and blocked with assay diluent for 1 h. They were then washed and incubated with 
100 µl of supernatants at room temperature for 2 h. Cytokine standards were serially 
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diluted from 2000 pg/ml to obtain standard curve in each individual assay. They 
were washed, and then 100 µl of the respective biotinylated secondary antibodies 
diluted in assay diluent was added and incubated for another 1 h. After extensive 
washing, streptavidin-HRP (1:2000) was added and incubated at room temperature 
for 30 min. After washing, 100 µl of ABTS (2, 2’-Azino-bis (3-ethyl-benzthiazoline-6-
sulphonic acid; Sigma) activated with H2O2 was added and absorbance was 
measured at 405 nm in an ELISA reader (Victor2™ 1420 mutilabel counter; Perkin 
Elmer life sciences). 
 
Serum antibody determination 
 
Plates were coated with rMOG (10 µg/ml in PBS) overnight at 4°C. ELISA was 
performed as above with 1:100 diluted serum samples and incubation of for 1 h. 
4.2.20 Enzyme linked immunospot (ELISPOT) assay 
 
ELISPOT plates (Millipore) were coated with rMOG as in ELISA. Serially diluted 
splenocytes or BM cells were plated, and the rest of the procedure was similar to 
that of ELISA. Streptavidin-alkaline phosphatase was used to reveal the biotinylated 
antibodies. BCIP/NBT (Sigma) substrate was added to visualize the antibody 
secreting cells, and spots were counted by an ELISPOT reader (Carl Zeiss). 
4.2.21 Quantitative real-time TaqMan PCR analysis 
  
PBMCs or spinal cord tissue was mixed or homogenized in 0.5 – 1 ml of TRI® 
reagent (Sigma). To this 200 µl of chloroform was added and centrifuged at 12000 
g/15 min. RNA was precipitated with 500 µl of isopropanol. It was washed once with 
75% ethanol and dissolved in RNAse-free water. RNA (~ 5 µg) was treated with 
DNAse to remove DNA contamination and reverse transcribed with either random 
hexamer or oligo-dT primer using Superscript II reverse transcriptase. All reagents 
for cDNA synthesis were obtained from Invitrogen. Sense and antisense primers in 
combination with FAM/TAMRA TaqMan probes and gene-specific primers 
(synthesized at Metabion, Martinsried, Germany) were utilized for PCR analysis. The 
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PCR reaction was carried out as described previously in genotyping. Each reaction 
was run in triplicate on an ABI 5700 machine (Applied Biosystems) and was 
normalized to house-keeping gene GAPDH transcripts. Primary data were analyzed 
with GeneAmp SDS 5700 software (PE Biosystems).  
4.2.22 Statistical analysis 
 
Data were analyzed with Microsoft Excel and GraphPad prism version 4. A two-
way ANOVA or t test was performed to analyze the statistical significance. A value of 
p < 0.05 was considered statistically significant.  
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5. RESULTS 
5.1 Double transgenic IgHMOG X TCRMOG (“Devic”) mice develop 
spontaneous EAE  
 
MOG 35 – 55-specific TCR (2D2) transgenic mice (TCRMOG) express the 
rearranged I-Ab restricted TCR. A large proportion (>30%) of these mice develop 
isolated spontaneous optic neuritis, but rarely EAE when observed for periods of up 
to 1 year (Bettelli et al., 2003).  
MOG-specific BCR (Th) “knock-in mice” (IgHMOG) contain the heavy chain of the 
demyelinating antibody 8.18-C5 and secrete large amounts of pathogenic 
antibodies. These mice never showed any spontaneous autoimmunity when 
observed over an extended period (Litzenburger et al., 1998).  
Interbreeding of TCRMOG and IgHMOG mice, both with the C57BL/6 genetic 
background and housed under specific pathogen-free (SPF) conditions, generated 
double transgenic mice that had both MOG-specific CD4+ T and B cells. These 
double transgenic mice were termed “Devic mice” (Figure 5.1A). Surprisingly, more 
than 50% of the Devic mice developed spontaneous EAE, while all single transgenic 
littermates remained disease-free during the 9-week (wk) observation period. In 
contrast, neither breeding of IgHMOG mice to non-self antigen ovalbumin (Ova 323 - 
339)-specific TCR transgenic mice (OT-II; Barnden et al., 1998) nor MOG-deficient 
Devic mice (Devic X MOG-/-; Delarasse et al., 2003) showed any spontaneous 
autoimmunity (Figure 5.1B). Clinical disease was observed at 6.1 ± 2 weeks of age, 
and the mean maximum disease score was 3.4 ± 1.2 (Table 5.1). Although male 
Devic mice showed a slightly earlier disease onset and a higher disease incidence 
than females, these differences were not statistically significant (Figure 5.1B). 
The microbial environmental might be important for precipitating autoimmunity. To 
determine whether different housing conditions (i.e., different microbial 
environments) could influence spontaneous EAE, Devic mice were also bred under 
conventional housing conditions. About 46% of these animals developed 
spontaneous EAE as did Devic mice housed under SPF conditions. A comparison of 
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the disease kinetics did not reveal any statistically significant difference (Figure 
5.1C). These data suggest that the presence of both MOG-specific T and B cells in a 
MOG-competent background is essential for spontaneous EAE. Environmental 
agents play (if at all) only a minor role in this spontaneous development.  
 
Figure 5.1 
Spontaneous EAE-like disease in double transgenic IgHMOG X TCRMOG (Devic) mice. (A) F1 double 
transgenic (IgHMOG X TCRMOG) mice, from interbreeding of TCR transgenic mice containing MOG 35-
55 specific CD4+ T cells and IgHMOG mice, which have MOG-specific B cells, were termed Devic mice. 
The genetic background of both parental mice was C57BL/6. (B) Spontaneous EAE-like disease was 
observed in Devic mice (red line) housed under SPF conditions, while single transgenic littermates 
IgHMOG (blue line) and TCRMOG (black line) did not show any clinical signs of EAE. Double transgenic 
IgHMOG X OT-II (ovalbumin specific TCR) mice (green dotted line) and MOG-deficient Devic mice 
(IgHMOG X TCRMOG X MOG-/-; violet dotted line) housed under the same conditions also never showed 
any clinical disease. Gray lines both above and below the red line show the disease kinetics of male 
and female Devic mice, respectively. The slightly earlier onset and higher incidence observed in male 
Devic mice (n = 73) when compared to female Devic mice (n = 60) was not statistically significant. (C) 
Devic mice housed under conventional conditions (n = 9) also showed EAE signs similar to the mice 
kept under SPF conditions (gray line; n = 133). Age-matched single transgenic littermates IgHMOG (n = 
7) and TCRMOG (n = 3) were free of clinical disease during the same observation period. 
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Table 5.1  
Spontaneous EAE incidence, onset, and severity in double transgenic IgHMOG X TCRMOG (Devic) 
mice. 
 
F1 mice from the interbreeding of IgHMOG with TCRMOG, IgHMOG with OT-II, as well as the IgHMOG and 
TCRMOG with MOG-/- were assessed for clinical signs of EAE at least once in 2 - 3 days. Clinical score 
and age at spontaneous onset of EAE in Devic mice are shown as mean ± SD calculated from closely 
observed mice (n = 8). NA, Not applicable. 
 
5.2 Causative CNS lesions in Devic mice mimic human opticospinal 
multiple sclerosis, Devic’s neuromyelitis optica 
  
The CNS of Devic mice with spontaneous EAE, housed under conventional 
conditions, was analyzed histologically. Pathological lesions in these mice were 
exclusively present in the optic nerves and spinal cord, whereas the brain was 
completely spared from any inflammation or tissue damage (Figure 5.2A). This 
peculiar localization of the lesions was highly similar to that in the human disease, 
Devic’s neuromyelitis optica, an MS variant. In contrast, age-matched single 
transgenic TCRMOG and IgHMOG mice did not develop any CNS lesions. Only seldom 
did a few TCRMOG animals show perivascular damage and mild infiltration. Healthy 
Devic mice also did not have any appreciable CNS lesions except sparse 
inflammatory infiltrates around perivascular areas (Figure 5.2B).  
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Figure 5.2 
CNS lesions in sick Devic mice resemble those in the human MS variant, Devic’s neuromyelitis 
optica. (A) A Devic mouse with clinical EAE was perfused transcardially with PFA, and after PFA 
fixation histological analysis was performed on different sections (cervical to lumbar) throughout the 
spinal cord. The histology of the entire CNS showed severe demyelination (red area) only in the optic 
nerve and the spinal cord, whereas the brain remained unaffected. (B) Analysis of the entire CNS of a 
healthy Devic mouse (7.5-wk-old) showed only slight focal inflammatory reaction (blue) in the optic 
nerve, whereas other parts of the CNS were completely free of any inflammation or demyelination. 
The histological analysis was performed by Prof. Hans Lassmann, University of Vienna, Austria. 
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Figure 5.3  
Histological analysis of optic nerves and spinal cords from a sick Devic mouse. Optic nerves (ON) (A-F) and spinal cords (G-N) 
were stained with hematoxylin & eosin (H&E), luxol fast blue (LFB), and Bielschowsky silver impregnation for cellular 
infiltration, demyelination and axonal damage, respectively. While hematoxylin/eosin stains mononuclear cells, luxol fast blue 
stains intact myelin as blue. Intact axons are stained dark brown with Bielschowsky silver impregnation and damaged axons 
stain yellowish brown. (A-C) The sections are from frontal brain sections and show both optic nerves; A: H & E; B: Luxol Fast 
Blue; C: Bielschowsky silver impregnation. Scale bar = 1mm. (D) Meninges surrounding the arterial spinalis anterior of the 
spinal cord with massive inflammatory infiltrates, composed of mononuclear cells and granulocytes, some of them being 
eosinophils; H&E staining; scale bar =100 µm. (E) Luxol fast blue staining of the anterior column of the spinal cord from the 
same animal. Shown is the actively demyelinating lesion (left side of the micrograph) with loss of myelin and Luxol fast blue 
myelin degradation products at the edge of the lesion. The asterisk shows the location of Fig 5.3 F; scale bar = 100µm. (F) 
Higher magnification of the lesion shown in Fig 1E, stained with Bielschowsky silver impregnation; profound reduction of axonal 
density and appearance of axonal spheroids, indicating acute axonal injury (arrow); scale bar= 100µm. (G-J) Conventional 
immunohistochemistry with antibodies against CD4, CD8, CD11b and B220/CD19 in the spinal cord. Shown is the predominant 
presence of CD11b+ macrophages (G) and CD4+ T cells (H) in the spinal cord, but B cells (I) and CD8+ cells (J) were not found 
in significant numbers. Arrows in G-J indicate the cells stained positive for the respective antibodies. Scale bar for G-J = 
100µm. The histological analysis was performed by Prof. Hans Lassmann, University of Vienna, Austria. 
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Furthermore, the CNS lesions of sick Devic mice were circumscript and contained 
massive numbers of the inflammatory cells. Pronounced demyelination and axonal 
damage were observed to coincide with the infiltration of inflammatory cells. 
Immunohistochemistry showed that the inflammatory infiltrates were predominantly 
composed of macrophages and CD4+ T cells (Figure 5.3).  
Occasionally a few B cells or CD8+ T cells were found. In some cases, significant 
numbers of eosinophils were also present in the actively demyelinating lesions 
(Figure 5.3). Devic mice kept under SPF conditions showed a similar localization of 
inflammatory lesions in the optic nerve and spinal cord with pronounced 
demyelination and massive infiltration of mononuclear cells in the meninges and 
perivascular areas. Eosinophilic infiltration was rarely observed. 
5.3 Th1-cytokine milieu in CNS lesions  
Cytokines and chemokines expressed by the CNS infiltrating cells create an 
inflammatory milieu and mediate the inflammatory process. The expression of 
cytokines and chemokines was assessed by quantitative real-time PCR of the spinal 
cords of Devic mice with spontaneous EAE, healthy IgHMOG, healthy TCRMOG, and 
wild-type C57BL/6 mice with actively induced EAE.  
 
Figure 5.4 
Th1 cytokine milieu of the spinal cord of sick Devic mice. Expression of cytokine and chemokine gene 
transcripts was measured by real-time quantitative PCR of the spinal cord of sick Devic (n = 5; clinical 
score ≥3), healthy IgHMOG (n = 3), healthy TCRMOG (n = 3), and MOG 35-55 immunized C57BL/6 (n = 
3; clinical score ≥ 3) mice. Relative expression levels were normalized to endogenous control gene 
GAPDH transcripts x 10,000. Error bars indicate the SEM. * = not detectable gene expression. 
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Th1 cytokine transcripts (IFN-γ, TNF-α) and chemokines (IP-10, eotaxin) were 
expressed at similar levels in sick Devic mice and in WT mice with active EAE. In 
contrast, Th2 cytokine transcripts (IL-4, -5 -10, -13) remained low or undetectable. 
Healthy TCRMOG or IgHMOG single-transgenic littermates did not show expression of 
any of these cytokine transcripts, but they did express eotaxin and IP-10, albeit at 
low levels compared to sick Devic mice (Figure 5.4). 
5.4 CNS-infiltrating transgenic CD4+ T cells are highly activated 
Consistent with the histological data, significant numbers of CNS infiltrating 
mononuclear cells could be isolated from the spinal cords of Devic mice with EAE by 
the percoll density gradient.  
 
Figure 5.5 
Transgenic CD4+ T cells infiltrating the CNS were highly activated. (A, B) Spinal cord infiltrated cells 
from sick Devic mice isolated by percoll gradient were stained with antibodies against CD4, CD3, and 
the activation markers CD25 and CD69. Gated CD4+CD3+ T cells expressed CD69, and some of 
them also expressed CD25. (C) CD4-CD3- cells stained for CD11b and B220 showed that they were 
predominantly CD11b+ macrophages and a very few B220+ cells were present. (D) CNS infiltrating 
CD4+ cells were mainly transgenic T cells stained by Vα3.2/Vβ11 TCR antibodies. (E, F) Splenocytes 
from the same mice stained by the same antibodies, in contrast, did not show any significant 
expression of CD25 and CD69. 
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In contrast, only a few cells (if any) could be recovered from the spinal cords of 
healthy Devic, IgHMOG, or TCRMOG mice. FACS analysis was performed to 
identify the cellular composition and the activation status of the spinal cord infiltrating 
cells. Splenocytes from the same sick Devic mice, which yielded ample numbers of 
mononuclear cells from CNS, were used as control. 
CNS infiltrating cells were mainly CD4+ T cells and CD11b+ macrophages, 
whereas CD8+ T cells and B cells were practically undetectable. These CD4+ T cells 
showed a highly activated phenotype when measured by the surface expression of 
CD25 (IL-2 receptor α chain) and CD69. In contrast, splenocytes from the same 
mice were not activated (Figure 5.5). 
5.5 Enhanced anti-MOG proliferative response in Devic mice 
splenocytes  
 
To determine the ability of transgenic splenocytes from Devic mice and single 
transgenic control mice to respond to the recombinant extracellular domain of MOG 
1-125 (rMOG) and MOG 35-55, the immunodominant peptides for I-Ab were 
analyzed in a proliferation assay. 
Dose response proliferation assays revealed that Devic mice splenocytes 
responded to rMOG by far more efficiently than TCRMOG or IgHMOG single transgenic 
splenocytes. While very low antigen doses (0.02 µg/ml) were sufficient to induce a 
significant proliferation in Devic splenocytes, high antigen doses (20 µg/ml) were 
required for a comparable proliferation of naive splenocytes obtained from TCRMOG 
mice. The proliferation of IgHMOG single transgenic splenocytes was the lowest of all, 
even at higher antigen dose (Figure 5.6A). In contrast, MOG 35-55 induced 
proliferation was similar in Devic and TCRMOG mice. Only a high peptide dose (20 
µg/ml) caused proliferation of Devic mice and TCRMOG mice splenocytes, whereas 
IgHMOG splenocytes completely failed to respond to MOG 35-55 (Figure 5.6B). 
Splenocytes contain many cell types besides the autoreactive T and B cells. To 
identify the molecular mechanisms and the cell types that contribute to this 
enhanced reactivity to rMOG protein, mixing experiments were performed with either 
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whole splenocytes or purified cells (>90% purity as judged by FACS staining). First, 
equal numbers of IgHMOG and TCRMOG splenocytes were combined, and a 
proliferation assay was performed with rMOG. This reproduced the dose response 
reactivity, which was similar to that of the double transgenic Devic mice. The mixing 
of TCRMOG or IgHMOG splenocytes with WT splenocytes, however, did not show 
enhanced proliferation (Figure 5.6C).  
 
 
Figure 5.6 
Enhanced MOG autoreactivity of Devic mice lymphocytes. (A, B) Dose response proliferation assay. 
Devic, IgHMOG, and TCRMOG splenocytes were incubated with increasing concentrations of rMOG (A) 
or MOG 35-55 (B). (C) Dose response proliferation assay of mixed splenocytes. Equal numbers of 
IgHMOG and TCRMOG, TCRMOG and WT, IgHMOG and WT splenocytes were mixed, and a proliferation 
assay was performed with increasing concentrations of rMOG. Cells were cultured for 3 days and 
pulsed with 3H-thymidine during the last 12 - 16 h. Cell-incorporated 3H-thymidine, which indicates 
proliferation, was analyzed by measuring radioactivity in a beta counter and shown it as counts per 
minute (cpm). Each sample was run in triplicate; error bars indicate SEM. Shown data represent more 
than five independent experiments. 
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Second, to determine the relative contribution of MOG-reactive B and T cells, both 
cell types were purified from single transgenic mice and Devic mice by a negative 
isolation method. FACS analysis showed that the purity of the cell types was more 
than 90% (data not shown). Non-transgenic B and T cells were purified from 
TCRMOG (TCR transgenic) and IgHMOG (B cell transgenic), respectively. A similar 
synergistic proliferation in response to rMOG was observed by mixing both MOG- 
specific T and B cells but not by mixing non-transgenic T and B cells (Figure 5.7A). 
Although enhanced proliferation was observed only when both MOG-specific B 
and T cells were present in the culture, it is not clear whether the role of B cells is 
limited to enhancing the proliferation of T cells or if both T and B cells stimulate each 
other to induce proliferation. To understand the mechanisms underlying this super-
proliferation, TCRMOG splenocytes were mixed with either irradiated or non-irradiated 
IgHMOG splenocytes. While the mixing of non-irradiated IgHMOG splenocytes 
reproduced the super-proliferation in response to rMOG, irradiation of IgHMOG 
splenocytes drastically reduced the proliferation. In contrast, MOG 35-55 induced 
proliferation was not affected by irradiation (Figure 5.7B). This is consistent with the 
fact that the transgenic heavy chain of IgHMOG B cells binds only the conformational 
epitope of MOG, but not the MOG 35-55 peptide. The observed synergistic 
proliferation is clearly due to the active co-operation between MOG-specific T cells 
and B cells, during which B cells efficiently bind and present antigen to the T cells. 
To further demonstrate the active co-operation between MOG-specific B and T 
cells, Devic mouse splenocytes were labeled with the carboxy-fluorescein diacetate 
succinimidyl ester (CFSE), which emits green fluorescence when excited, and 
stimulated with rMOG. Cell proliferation was monitored by diluting cellular CFSE. 
FACS analysis of rMOG-stimulated CFSE-labeled splenocytes showed that both T 
and B cells proliferated equally (Figure 5.7C). The active co-operation between T 
and B cells was further substantiated by upregulation of the activation marker CD25 
on T cells and the co-stimulatory molecule CD86 on the B cells (Figure 5.7D). 
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Figure 5.7 
Active co-operation of MOG-specific T and B cells. (A) Purification and mixing of transgenic and non-
transgenic CD4+ T and B cells. Equal numbers of highly purified CD4+ T cells and B cells from 
TCRMOG or from IgHMOG were mixed as indicated and exposed to increasing concentrations of rMOG. 
Proliferation was measured by the 3H-thymidine incorporation assay. (B) TCRMOG splenocytes were 
mixed with equal numbers of either irradiated or non-irradiated IgHMOG splenocytes. The proliferation 
in response to MOG 35-55 (20 µg/ml) and rMOG (20 µg/ml) was measured by the 3H-thymidine 
incorporation assay. (C) Devic mouse splenocytes were labeled with CFSE and exposed to optimal 
concentration of rMOG in vitro for 3 days. The proliferation of T and B cells (revealed by CD4 and 
B220 staining) was measured by diluting cellular CFSE (filled histogram) compared to no antigen 
control (open histogram). (D) FACS analysis of expression of the activation markers CD25 and CD86 
by Devic mouse T and B cells, respectively, after activation with rMOG. Each sample in figures A and 
B was run in triplicate; error bars indicate SEM. *** - indicates statistical significance (p < 0.001). 
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5.6 Rapid activation and co-stimulatory expression of Devic 
lymphocytes in vitro  
 
The enhanced reactivity of Devic lymphocytes to rMOG suggested efficient co-
operation between MOG-specific T and B cells. The interaction between T and B 
cells is mediated by several cell surface molecules. For example, B cells present 
processed antigen to the CD4+ T cells by MHC class II molecules. In addition, 
several cell surface, positive and negative co-stimulatory, molecules on the B cells 
interact with their respective ligands that are expressed on T cells to modulate the 
immune response. While positive co-stimulatory molecules such as CD80 (B7.1) and 
CD86 (B7.2) amplify the response, negative co-stimulatory molecules such as 
CTLA-4 and PD-1 dampen the reactivity to control an unwanted immune response. 
 Previous experiments measured the response of Devic lymphocytes to rMOG 
after 3 days of stimulation. To understand the kinetics of enhanced reactivity, Devic 
and single transgenic splenocytes were exposed to 20 µg/ml rMOG or remained 
without antigenic stimulus for 24 h. Expression of the activation markers CD25, 
CD44, and CD69, downregulation of CD62L, and expression of co-stimulatory 
molecule CD154 (CD40L) were measured by FACS. 
CD4+ T cells from Devic and TCRMOG mice but not IgHMOG mice rapidly 
upregulated CD25, CD69, and CD44 and downregulated CD62L after rMOG 
stimulation. The percentage of T cells of Devic mice expressing these molecules 
was considerably higher than T cells of TCRMOG mice. In contrast, CD154 (CD40L) 
expression was not detectable in T cells of any mice (Figure 5.8 A & B). Stimulated 
Devic B cells (either B220+ or CD19+) upregulated CD69 and CD86, while CD80 
expression was not modulated (Figure 5.8 C & D). These data demonstrate that 
significant numbers of Devic T cells are rapidly activated upon rMOG stimulation. 
Next, the expression of co-stimulatory molecules on T and B cells was measured 
with or without rMOG stimulation (Figure 5.9). Large numbers of unstimulated B cells 
from IgHMOG, TCRMOG, and Devic mice expressed PDL-1 (programmed death ligand 
1) and ICOSL (inducible co-stimulator ligand) constitutively. Although the percentage 
of B and T cells expressing PDL-1 was similar in all mice and was not altered by 
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rMOG stimulation, the cellular amount, measured by the mean fluorescence 
intensity, was significantly increased in rMOG-stimulated lymphocytes (Figure 5.10). 
 
 
 
Figure 5.8 
Rapid activation of Devic lymphocytes by rMOG in vitro. Devic, IgHMOG and TCRMOG , splenocytes 
were either left untreated (A, C) or exposed to 20 µg/ml of rMOG (B, D) for 24 h. Cells were stained 
with antibodies against CD154, CD62L, CD69, CD44, and CD25 and analyzed by FACSCalibur. 
Upregulation or downregulation (as indicated in the figure) of these molecules is shown as % of CD4+ 
T cells (A, B) and B220+ B cells (C, D). 
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Figure 5.9 
Expression of co-stimulatory molecules by transgenic lymphocytes after rMOG stimulation in vitro. 
Devic, IgHMOG , and TCRMOG splenocytes were either left untreated (A, C) or incubated with 20 µg/ml 
rMOG (B, D) for 24 h. Cells were stained with fluorochrome conjugated antibodies and analyzed by 
FACSCalibur. Percentages of gated CD4+ T cells (A, B) and gated CD19+ B cells (C, D) are shown. 
 
The increased amount of PDL-1 on the surface of Devic T cells was similar to 
TCRMOG T cells. In contrast, IgHMOG T cells did not show a significant increase in 
PDL-1 surface expression. Upregulation of PDL-1 was observed on all rMOG 
stimulated B cells, although highest expression was detected among stimulated B 
cells from Devic spleen (Figure 5.10). B cells of Devic and TCRMOG mice down-
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regulated their constitutive ICOSL expression after treatment with rMOG, whereas 
about 40% of the IgHMOG B cells retained ICOSL expression (Figure 5.9). 
 
 
Figure 5.10 
PDL-1 expression on transgenic T and B cells after in vitro rMOG stimulation. Devic, IgHMOG , and 
TCRMOG splenocytes were either left untreated or incubated with 20 µg/ml rMOG for 24 h. Cells were 
stained with fluorochrome conjugated antibodies and analyzed by FACSCalibur. PDL-1 expression 
measured by the mean fluorescence intensity of gated CD4+ T cells (A) and gated CD19+ B cells (B) 
are shown. 
 
High frequencies of T cells from all mice expressed CD28 and PDL-1, 
independently of whether they were activated with rMOG or remained without a 
stimulus. It is of interest that a large proportion of T cells from TCRMOG and Devic but 
not IgHMOG spleens expressed the ICOS molecule when stimulated with rMOG. In 
contrast, PD-1 expression was detectable only in a negligible fraction of Devic T 
cells. Of note, ICOSL, PDL-2, and CTLA-4 on T cells and PDL-2, PD-1, ICOS, 
CD28, and CTLA-4 on B cells were not detected before or after rMOG activation 
(Figure 5.9). 
5.7 Devic lymphocytes produce Th1 cytokines in vitro  
 
The effector function of lymphocytes depends on the cytokines produced by them. 
To determine which cytokines are secreted by the lymphocytes, splenocytes from 
single transgenic mice and Devic mice were cultured in the presence of either MOG 
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35-55 or rMOG. Supernatants from stimulated cultures were collected 3 days after 
stimulation, and cytokines were measured by a sandwich ELISA. 
Devic splenocytes secreted predominantly Th1 cytokines in a dose-dependent 
manner (Figure 5.11). Like the enhanced proliferation, the secretion of significant 
amounts of cytokines was noted in Devic splenocytes stimulated with even minute 
amounts of rMOG; in contrast, TCRMOG and IgHMOG splenocytes required much 
higher concentrations of rMOG. The Th1 cytokines IFNγ and IL-2 were prominent in 
the supernatants, whereas Th2 cytokine production was low. IL-4 was only 
marginally detectable, and low levels of IL-5 were evident only in Devic splenocytes 
stimulated with rMOG. In contrast, MOG 35-55 stimulation, much like proliferation, 
did not induce cytokine secretion at enhanced kinetics as observed with rMOG 
stimulation (Figure 5.11).  
To determine which cell type(s) produce cytokines in response to rMOG in vitro, 
Devic splenocytes were labeled with CFSE, stimulated with rMOG, and intracellular 
cytokine staining was performed (Figure 5.12). T and B cells were distinguished by 
co-staining with anti-CD4 and anti-B220 antibodies, respectively. Stimulated but not 
unstimulated CD4+ T cells from Devic mice produced TNFα and IFNγ, whereas B 
cells from the same cultures did not produce these cytokines. TNFα producing Devic 
T cells appeared as early as 24 h (day 1) after stimulation. Their numbers were 
gradually reduced by days 2 and 3 (Figure 5.12 A). The frequency of TNFα 
producing Devic T cells showed a clear dose-dependent response to rMOG (Figure 
5.12 D). 
In contrast, TCRMOG single-transgenic T cells did not produce TNFα (Figure 5.12 
D). Devic T cells also expressed IFN-γ when stimulated with rMOG. However, the 
kinetics of IFN-γ production was significantly slower when compared to TNFα 
production. Moreover, the frequency of IFN-γ+ T cells was relatively low (Figure 5.12 
C). IgHMOG T cells did not produce any of the tested cytokines (Figure 5.12). 
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Figure 5.11 
Enhanced cytokine secretion by Devic mice lymphocytes. Devic mice, IgHMOG, and TCRMOG 
splenocytes were incubated with increasing concentrations of rMOG (A-D) or MOG 35-55 (E-H) for 3 
days. Cytokines released from stimulated cultures were measured by sandwich ELISA. Absolute 
amounts of IFNγ (A, E), IL-2 (B, F), IL-4 (C, G) and IL-5 (D, H) were calculated from standard curve 
constructed using recombinant cytokine standard. Representative results of a total of seven Devic, 
three TCRMOG, and three IgHMOG animals analyzed during three independent experiments. Error bars 
indicate the SEM. 
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Figure 5.12 
Relative contribution of Th1 cytokine secretion by T and B cells. (A, B) show the intracellular TNFα 
FACS staining of rMOG stimulated (20 µg/ml) Devic mouse splenocytes. Brefeldin A was added to 
stimulated cells for 6 h before FACS staining on day 1 (left panel), day 2 (middle panel) and day 3 
(right panel) and stained with antibodies against CD4, CD19, and TNF as described in the Methods. 
(C, D) Devic, TCRMOG and IgHMOG splenocytes were stimulated in vitro with rMOG as indicated, and 
the frequency of TNFα and IFNγ secreting CD4+ T cells was quantified on day 1, 2, and 3 after 
stimulation. Values are expressed as percentage of gated CD4+ T cells. 
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5.8 In vivo antigen presentation in Devic mice 
 
To address the question as to whether the efficient antigen presentation by MOG-
specific B cells observed in vitro is also applicable in vivo, naive rMOG-incubated 
IgHMOG splenocytes were adoptively transferred to TCRMOG mice.  
 
 
Figure 5.13 
MOG-incubated transgenic B cells transfer EAE. (A) Depicts the strategy to evaluate the antigen 
presentation efficiency of MOG-specific B cells in vivo. IgHMOG spleen cells were incubated with MOG 
or ovalbumin for 10 min and transferred into TCRMOG mice. (B-D) Spinal cord with large inflammatory 
demyelinating lesions mainly in the anterior and lateral columns. (B) H&E showing inflammation; (C) 
Luxol fast blue showing demyelination; (D) Bielschowsky silver impregnation showing axonal loss; 
Scale bar of B-D = 1mm (E-G) Serial sections through optic nerve and chiasm with inflammatory 
demyelinating lesions. (E) H&E; (F) Luxol fast blue; (G) Bielschowsky silver impregnation. Scale bar 
of E-F = 1mm. The histological analysis was performed by Prof. Hans Lassmann, University of 
Vienna, Austria. 
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Brief incubation (10 min) with rMOG protein might facilitate antigen uptake, if any, 
by the transgenic B cells via their surface Ig. Subsequently, the cells were washed 
extensively to remove unbound protein and transferred via the tail vein into TCRMOG 
mice. As a control, ovalbumin-incubated IgHMOG splenocytes were transferred into 
TCRMOG mice at the same time. Some animals additionally received LPS (50 
µg/mouse; i.p.), which is known to activate B cells (Figure 5.13). The transfer of 
MOG-incubated splenocytes, but not ovalbumin-incubated splenocytes, induced 
EAE in about 20% of the mice. Further, activation of B cells by LPS did not 
significantly alter the incidence of EAE (Table 5.2). Histological examination of the 
sick mice showed the presence of mononuclear cells in the spinal cord and optic 
nerve. This was similar to the Devic mice with spontaneous EAE. In addition, they 
exhibited a loss of myelin and moderate axonal damage (Figure 5.13).  
 
Table 5.2 
Incidence of EAE following adoptive transfer of MOG or ovalbumin incubated IgHMOG splenocytes. 
 
 
IgHMOG splenocytes were incubated with rMOG or ovalbumin (1 µg/1 × 106 cells) for 10 min at 37°C 
and washed extensively. 20 × 106 cells were transferred i.v. into TCRMOG mice and observed for 
clinical signs of EAE for 30 days. 
5.9 Anti-MOG autoantibodies and their influence in Devic mice 
Autoreactive B cells differentiate with the help of T cells to produce self-reactive 
antibodies, which recognize self-antigens and induce tissue damage. To analyze the 
changes in humoral immunity and the ability of Devic mice to secrete self-reactive 
antibodies, total serum immunoglobulins (Ig), and MOG-specific Ig were measured 
by ELISA. Serum from Devic mice, control single transgenic littermates, IgHMOG X 
OT-II double transgenic mice, and Devic X MOG KO mice were used. 
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Devic mice did not differ from their single transgenic parental IgHMOG and TCRMOG 
mice in the absolute amounts of total serum IgM, IgG1 or IgG2b levels. However, 
there was a slight reduction in the IgG3 levels and an increase in the IgG2a amounts 
(Figure 5.14). This indicates that Devic mice have no major abnormalities in their 
humoral immunity.  
 
Figure 5.14 
Total serum Ig levels. 1:100 diluted serum, collected by retro-orbital puncture, from Devic and single 
transgenic littermates was measured for the presence of IgM (A), IgG1 (B), IgG2a (C), IgG2b (D), 
and IgG3 (E) by an isotype specific sandwich ELISA. Purified antibodies were used as standard to 
quantify the absolute amounts. Mean values are indicated for each animal group (n = 5 – 6). * 
indicates statistical significance (p < 0.01). 
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Subsequently, MOG-specific antibodies were measured from the serum of these 
transgenic mice. Strikingly, Devic mice differed from single-transgenic IgHMOG mice 
in the amounts of MOG-specific IgG1 serum autoantibodies. While MOG-specific 
IgM antibodies were readily detectable in the serum of IgHMOG animals, MOG-
specific IgG1 antibodies remained at low serum titers in these mice. In contrast, 
Devic mice produced high serum levels of anti-MOG antibodies of both IgM and 
IgG1 isotypes. MOG-specific antibodies could not be detected in naive TCRMOG 
mice. However, anti-MOG IgG1 antibodies were observed irrespective of the clinical 
status of the Devic mice. Interestingly, Devic mice deficient in MOG (i.e. triple-
transgenic IgHMOG x TCRMOG x MOG-/- mice) also had elevated serum levels of 
MOG-specific IgG1 antibodies. This indicates that a spontaneous isotype switching 
of MOG-specific antibodies from IgM to IgG1 isotopes occurred independently of 
MOG antigen.  
 
Figure 5.15 
MOG-specific serum autoantibodies in transgenic mice. Sera obtained from healthy (n = 18) and sick 
(n = 24) Devic, healthy IgHMOG (n = 16), healthy OT-II (TCROVA) x IgHMOG (n = 7), and healthy Devic x 
MOG KO (n = 3) mice were diluted to 1:100 and incubated with plates coated with rMOG. Bound 
MOG-specific Ig was detected by allotype/isotype specific antibodies recognizing IgMa, IgG1a, or 
IgG2a/ba. Values are expressed as the mean absorbance (at OD 405 nm) measured during more 
than five independent experiments. Error bars indicate the SEM.  
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This spontaneous isotype switching was observed only in Devic mice, 
whereas double transgenic IgHMOG x OT-II, which contain non-self antigen 
ovalbumin-specific TCR together with IgHMOG, did not have high amounts of MOG- 
specific IgG1. However, these mice had similar titers of MOG-specific IgM 
autoantibodies (Figure 5.15). 
Antibody secreting cells (ASCs) can be identified by an ELISPOT assay. To 
understand the anatomical location where the MOG-specific B cells undergo 
spontaneous isotype switching, bone marrow (BM) cells and splenocytes, in which 
isotype switching presumably happens, were plated onto rMOG-coated plates for 
either a brief period (5 h) or overnight (12-16 h). Subsequently, bound antibody 
secreting cells were detected by isotype-specific antibody. The IgM ASCs were 
present in the BM as well as in splenocytes, but IgG1 ASCs were neither detectable 
among splenocytes nor among bone marrow cells obtained from either healthy or 
sick Devic mice (Figure 5.16). This suggests that isotype switching most likely 
occurred outside the BM and spleen at an as yet unidentified location.  
 
 
 
Figure 5.16 
Anti-MOG autoantibody-secreting cells in transgenic mice. Serially diluted bone marrow cells and 
splenocytes were seeded onto the rMOG-coated plates and after 5 h bound anti-MOG antibody- 
secreting cells were visualized by the isotype/allotype specific secondary antibody with BCIP/NBT as 
substrate. The number of spots, indicating the antibody-secreting cells, was counted (dilution gives 
clearly countable spots) by the Carl Zeiss ELISPOT reader. Data are expressed as the number of 
spots per million cells + SEM. The data is representative of two  independent experiments. 
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IgHMOG B cells express the heavy chain of the anti-MOG antibody 8.18-C5 which 
is paired with the endogenous light chains. FACS analysis showed that about 30% 
of B cells in these mice bind MOG. To analyze the MOG-binding activity and 
possibly to isolate MOG binding IgG1 B cells, a significant number of hybridomas 
(see table 5.3) were produced from splenocytes of healthy IgHMOG and healthy or 
sick Devic mice by standard techniques. Hybridoma supernatants were screened for 
the presence of MOG-binding Ig and their isotype.  
 
Table 5.3 
B cell hybridomas from splenocytes of transgenic mice 
 
Devic and IgHMOG mice splenocytes were stimulated with LPS for 2 days. After washing, the activated 
B cells were fused with non Ig secreting Sp2/0 cells using polyethylene glycol and were plated on 96-
well plates. Growing clones were expanded, and supernatants were screened for the presence of 
MOG-binding antibodies of IgM or IgG1 isotype by ELISA. Some master hybridomas were cloned by 
single cell sorting, were expanded, and supernatants were assayed for the MOG-binding antibodies 
by ELISA. ND, not determined 
 
Fusion of LPS-activated IgHMOG or Devic splenocytes with the non-Ig producing 
hybridoma cell line Sp2/0 yielded several antibody-producing hybridomas. 
Surprisingly, the screening of hybridomas that contained more than one antibody-
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secreting cell (master hybridoma) revealed that all of them were of the IgM isotype 
and able to bind MOG. In view of the fact that only 30% of the transgenic B cells 
bind MOG in FACS assays, the ability of all the generated hybridomas to bind MOG 
is contradictory. In addition, no single IgG1- secreting hybridoma was found. Some 
master hybridomas were sub-cloned by single cell sorting. Analysis of the sub-
clones showed that all of them also bound MOG and they were of the IgM isotype 
(Table 5.3). These data point out that IgG1 isotype switching must happen outside 
the spleen and/or at low frequency. 
Isotype switching is a highly co-ordinated event that requires the interaction of T 
cells and B cells and is facilitated by certain cytokines. Furthermore, the interaction 
of constitutively expressed CD40 on B cells and CD40L (CD154) expressed on 
activated T cells leads to a pronounced expansion and differentiation of B cells into 
Ig- secreting plasma cells. It has been reported that the blockade of the interaction of 
CD40 – CD40L prevents isotype switching (Howard et al., 1999). 
Initially, the effect of MR1 (anti-mouse CD40L) antibody on the rMOG-induced 
proliferation of Devic splenocytes was measured by the thymidine incorporation 
assay. It was observed that the blockade of CD40L significantly reduced the in vitro 
proliferation of Devic splenocytes (Figure 5.17 A). However, in vivo administration of 
the anti-CD40L antibody to young Devic and IgHMOG mice (3 – 4-wk-old) did not 
prevent a spontaneous isotype switching from MOG-specific IgM to IgG1. The levels 
of MOG-specific antibodies were comparable in MR1 antibody- and PBS-treated 
Devic mice. MOG-specific IgM antibody levels were unaffected in IgHMOG or in Devic 
mice after CD40L blockade (Figure 5.17 B).  
 
Results 
 
68
 
Figure 5.17 
Effect of CD40L blockade on in vitro proliferation and in vivo isotype switching. (A) Dose response 
proliferation of Devic splenocytes to rMOG with or without the presence of 10 µg/ml MR1 (anti-mouse 
CD40L). Data shown as mean cpm measured by 3H-thymidine incorporation ± SEM measured from 
triplicates. *** indicates statistically significant (p < 0.01). (B) Serum MOG-specific antibody levels of 
PBS or MR1 antibody-treated IgHMOG and Devic mice (three mice per group). 1:100 diluted serum 
samples were incubated with MOG-coated plates, and bound Ig was detected by isotype/allotype 
specific antibody. Values are expressed as mean absorbance at 405 nm + SEM. 
 
Table 5.4 
Incidence of spontaneous EAE after in vivo CD40L blockade 
 
500 µg MR1 (anti-CD40L) antibody were injected into young (3 - 4 wk-old) Devic and IgHMOG mice on 
days 0, 3, 6, and the incidence of spontaneous EAE was monitored for 60 days. 
 
CD40L blockade also did not prevent spontaneous EAE in Devic mice. MR1 
antibody treatment did not induce EAE in single transgenic IgHMOG mice (Table 5.4). 
Spleen cells from these antibody-treated mice were isolated after 2 months and 
evaluated for the proliferation in response to rMOG. Surprisingly, the MR1-antibody 
treated mice splenocytes proliferated more strongly than PBS-treated mice (Figure 
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5.18). This paradoxical in vivo effect when compared to the inhibition of in vitro 
proliferation by the MR1 antibody may be due to the multiple effects of CD40L 
blockade in vivo. 
 
 
Figure 5.18 
Effect of in vivo CD40L blockade on proliferation. 500 µg MR1 (anti-CD40L) antibody were injected 
into young (3 - 4 wk-old) Devic and IgHMOG mice on days 0, 3, 6, and splenocytes were isolated after 
the mice developed spontaneous EAE (~2 months). Splenocytes were exposed to increasing 
concentrations of rMOG, and proliferation was measured by the 3H-thymidine incorporation assay. 
Shown as mean cpm ± SEM measured from triplicate samples. 
5.10 Activation status of lymphocytes in Devic mice 
 To understand which peripheral changes lead to the development of spontaneous 
EAE, a FACS analysis was performed on the splenocytes obtained from Devic mice 
and single transgenic control mice.  
Healthy Devic mice and single transgenic mice did not differ in the absolute 
numbers of their splenocytes. There was a slight reduction in the total numbers of 
splenocytes from sick Devic mice. Splenocytes were stained with fluorochrome- 
conjugated antibodies against various cell surface markers to further clarify their 
cellular composition. The percentage of the B220+ or CD19+ cells, CD4,+ and CD3+ 
T cells was similar in all groups, whereas only a few CD8+ T cells were present in 
Devic and TCRMOG mice when compared to IgHMOG mice (Table 5.5). 
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Table 5.5 
Total cell numbers and composition of splenocytes from Devic and single transgenic mice. 
 
* The amounts of total splenocytes ± SD. Number of animals analyzed: Devic healthy, n=14; Devic 
sick, n = 15; TCRMOG, n = 14; IgHMOG, n = 13. § indicates the percentage of the indicated cell type 
among live-gated splenocytes ± standard deviation. Number of animals analyzed: Devic healthy, n=3; 
Devic sick, n = 12; TCRMOG, n = 7; IgHMOG, n = 7. 
 
Naive lymphocytes, which normally do not cross the blood-brain barrier, might 
enter the CNS after activation in peripheral lymphoid organs. It is well documented 
that activated lymphocytes express several distinct surface markers. To identify the 
activation status of the T and B cells, splenocytes were stained with several surface 
markers. It was found that B cells obtained either from healthy IgHMOG or Devic mice 
expressed comparable amounts of CD80, CD86, and MHC class II (Figure 5.19). 
Likewise, B cells from sick Devic mice showed very similar levels of surface 
expression of these markers, indicating that their peripheral B cells were not strongly 
activated. 
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Figure 5.19 
The expression of activation markers in B cells of transgenic mice. RBC-depleted splenocytes from 
IgHMOG and Devic mice were stained with fluorochrome-conjugated antibodies against CD80, CD86, 
and MHC class II and CD19. Samples were acquired in FACSCalibur and analyzed by WinMDI 
software.  Numbers in quadrants refer to the percentage of the gated-cell population. 
 
IgHMOG transgenic B cells efficiently bind MOG via their cell surface IgM. To test 
whether the enhanced proliferation and cytokine secretion are due to an increase in 
the capacity to bind MOG antigen by transgenic B cells, splenocytes from IgHMOG 
and Devic mice were incubated with labeled rMOG protein and analyzed by FACS. 
About 20 - 30% of the single-transgenic IgHMOG B cells were able to bind MOG 
through their surface IgM. Devic mice also showed similar MOG binding, 
quantitatively and qualitatively, irrespective of the clinical status of the animals. 
Moreover, the number of B cells expressing the transgenic heavy chain (IgMa 
allotype) was similar in Devic and IgHMOG mice, and there was no change in the 
expression of the endogenous heavy chain (IgMb allotype; Figure 5.20). 
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Figure 5.20 
MOG binding by transgenic B cells from Devic mice and single transgenic IgHMOG mice. Splenocytes 
from Devic mice and IgHMOG mice were stained with antibodies against IgMa (transgenic allotype), 
IgMb (wild-type allotype), B220, and biotinylated rMOG. Streptavidin-APC was used to develop biotin 
conjugate. Results are shown as B220 gated cells. (A) and (B) refer to the expression of the 
transgenic heavy chain in B cells of IgHMOG and Devic mouse, respectively. (C) and (D) show the 
ability of transgenic B cells IgHMOG or Devic mice, respectively, to bind MOG. Numbers in quadrants 
indicate the percentage of the gated-cell population. 
 
Activated, but not naive, T cells express several specific surface molecules. 
Analysis of TCRMOG and Devic mice for the expression of the activation markers 
CD25 (IL-2 receptor α chain), CD69, CD44, and CD62L (L-selectin) revealed no 
significant difference, irrespective of the clinical status of the mice (Figure 5.21). 
The above data demonstrate that there is minimal activation of lymphocytes in 
peripheral lymphoid organs of Devic mice. To verify and delineate the location of T 
cell activation, adoptive transfer experiments were performed. Naive Devic mouse 
splenocytes were labeled with CFSE in vitro and injected i.v. into sick as well as 
healthy Devic mice. CNS infiltrating cells and splenocytes were harvested after 3 
days and analyzed for dilution of cellular CFSE (indication of T cell proliferation) and 
for expression of CD69. Percoll gradient separation yielded significant numbers of 
cells from the spinal cord of sick Devic mice, but only a few cells (if any) could be 
recovered from healthy mice.  
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Figure 5.21 
Activation status of T cells in transgenic mice. Splenocytes from TCRMOG and Devic mice with EAE 
(Score 4) were stained with antibodies against CD69, CD44, CD62L, and CD4. Results shown are 
gated on CD4+ T cells. Numbers in quadrants refer to percentage of the gated cell populations.  
 
Cells isolated from the spinal cord of sick Devic mice contained significant 
numbers of CD4+ T cells, but only a very few CD19+ B cells (Figure 5.22 A). While in 
the spleen, CFSE-loaded cells showed a meager proliferation, CNS infiltrated T cells 
proliferated vigorously, as indicated by the decrease in the fluorescence intensity of 
CFSE. CNS-infiltrated cells expressed the activation marker CD69 at comparable 
levels to that of host-derived cells (CFSE negative quadrant; Figure 5.22). It can be 
concluded that the CNS is a major site of T cell activation. 
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Figure 5.22 
Proliferation of T cells in the CNS. (A) Percoll gradient separated CNS infiltrating mononuclear cells 
(3 days after injection) from sick Devic mice, which received CFSE-labeled naive Devic splenocytes 
stained for CD4, CD69, and CD19. Right panel shows gated CD4+ T cells for the expression of CD69 
and CFSE fluorescence. (B) Splenocytes from the same sick mice stained as above. CFSE 
fluorescence in gated CD4+ T cells is shown in right panel. 
 
5.11 Reconstitution of wild-type (WT) mice with Devic mice bone 
marrow (BM) reproduces spontaneous EAE 
To further clarify whether bone marrow-derived B and T cells or yet another defect 
in the architecture of Devic mice induces spontaneous EAE, bone marrow 
reconstitution experiments were performed.  
Lethally irradiated WT C57BL/6 mice were reconstituted with bone marrow cells 
derived from Devic mice. Analysis of the PBMCs 1 month after injection confirmed 
the reconstitution of the immune system with the transgenic T and B cells. 
Reconstituted mice also showed high titers of serum MOG-specific IgG1 
autoantibodies as commonly found in Devic mice. In contrast, titers of MOG-specific 
IgM autoantibodies were significantly low (Figure 5.23 A). Despite the reconstitution 
of WT mice with transgenic B and T cells and the isotype switching to IgG1 
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autoantibodies, the disease incidence in these mice was surprisingly low (12.5%). 
Those few chimeric mice that had developed spontaneous EAE-like disease 
exhibited CNS lesions only in the optic nerves and spinal cord with severe 
demyelination and axonal damage (Figure 5.23 B & C). This clearly shows that 
transgenic MOG-specific B cells and T cells can induce spontaneous EAE-like 
disease, which is dependent on other endogenous factors. 
 
 
Figure 5.23 
BM reconstitution reproduces spontaneous EAE. (A) Serum MOG-specific antibody levels 1 month 
after Devic BM injection into WT mice (n = 7). ** indicates statistically significant (p < 0.01). (B, C) 
Histological analysis of the spinal cord and optic nerve from BM reconstituted mice with spontaneous 
EAE. (B) Serial sections through optic nerve (longitudinal sections) showing demyelinated plaques in 
Luxol fast blue staining (upper picture) and inflammatory infiltrates in H&E staining (lower picture). 
Scale bar = 1mm. (C) Spinal cord with inflammatory demyelinating lesions mainly in the left anterior 
column; upper picture: H&E, lower picture: Luxol fast blue. Scale bar = 1mm. The histological analysis 
was performed by Prof. Hans Lassmann, University of Vienna, Austria. 
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5.12 Devic lymphocytes transfer spontaneous EAE in 
immunodeficient mice. 
 The use of adoptive transfer models allows determination of the relative 
contribution of specific cells types that are necessary to induce EAE. To establish an 
adoptive transfer model of Devic mice, naive splenocytes from healthy Devic mice 
were injected into recombinase-activating gene 2-deficient mice (RAG2 KO), which 
lacked T and B cells. RAG2 KO mice, however, are normally able to present antigen 
and show normal amounts of NK cells. The transfer of splenocytes from naive 
healthy young (< 8-wk-old) Devic mice into RAG2 KO mice induced severe 
spontaneous EAE in 75% of the recipient animals 13.7 ± 2.2 days after transfer. In 
contrast, TCRMOG splenocytes transferred into RAG2 KO mice induced a low 
incidence of EAE, and IgHMOG splenocytes did not transfer EAE (Table 5.6).  
 
Table 5.6 
Incidence of EAE following adoptive transfer of Devic and single transgenic mice splenocytes into 
RAG KO mice. 
 
Devic or single transgenic mice splenocytes (50 × 106) were transferred into RAG-deficient mice and 
the incidence of spontaneous EAE was noted. Data pooled from two independent experiments. NA- 
Not applicable. 
 
Histological analysis of the spinal cord from sick mice that received Devic 
splenocytes showed lesions, infiltration, and demyelination similar to that in Devic 
mice (data not shown). Analysis of serum immunoglobulin identified MOG-specific 
IgM antibodies in RAG2 KO mice which had previously received Devic or IgHMOG 
splenocytes. Surprisingly, the spontaneous isotype switching to IgG1 observed in 
Devic mice was completely absent in these mice. In addition, mice that received 
IgHMOG splenocytes showed high titers of MOG-specific IgG2a/2b levels in their 
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serum. In contrast, TCRMOG cell transfer did not produce any MOG-specific 
antibodies (Figure 5.24). 
 
 
Figure 5.24 
Serum immunoglobulin levels after adoptive transfer. Devic or single transgenic mice splenocytes (50 
× 106) were transferred into RAG-deficient mice. Serum was collected at least 12 days after transfer, 
and MOG-specific antibodies were measured by sandwich ELISA. Number of animals: TCRMOG 
transfer, n = 4; IgHMOG transfer, n = 2; Devic transfer, n = 7. 
 
To determine if any peripheral proliferation or activation occurs in this adoptive 
transfer EAE, Devic and OT-II X IgHMOG splenocytes were labeled with CFSE before 
transfer into RAG recipients. Mice were bled every 3rd day to identify proliferation 
indicated by CFSE-negative cells; CFSE+ cells indicate non-proliferated cells. Both 
control (OT-II X IgHMOG) and Devic T cells proliferated equally in RAG-/- mice but 
without any appreciable activation as measured by the surface expression of CD25 
(data not shown). The B cells initially underwent rapid proliferation, but the numbers 
stayed constant throughout the observation period (Figure 5.25).  
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Figure 5.25 
Proliferation of T and B cells following adoptive transfer. Devic and OT-II X IgHMOG splenocytes were 
labeled with CFSE and injected into RAG2 KO mice via the tail vein. Mice were bled every 3rd day 
and stained with antibodies against CD4 and B220. Green CFSE fluorescence-positive and negative 
CD4+ T cells and B220+ B cells were quantified. Each data point represents the mean percentage of 
gated cells from three animals. Error bars indicate SEM. 
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5.13 Regulatory T cells and their influence on spontaneous EAE 
 Although pathogenic T cells and B cells are present in normal individuals, they 
might be kept under control by several tolerance mechanisms. Regulatory cells, 
which exclusively express the transcription factor FoxP3, may be able to dampen 
self-reactive cells and hence prevent autoimmunity.  
 
Figure 5.26 
Expression of Foxp3 in the spleen of transgenic mice. Foxp3 transcripts from splenocytes of 4 – 8 wk- 
old transgenic mice were measured by quantitative real-time PCR. Each sample was measured in 
triplicate. Values are expressed as mean percentage of endogenous gene GAPDH transcripts + 
SEM. Data were pooled from more than three independent experiments. Numbers of animals 
analyzed: Devic healthy, n = 9; Devic sick, n = 9; TCRMOG, n = 7; IgHMOG n = 8.  
 
Expression of Foxp3 was measured by the quantitative real-time PCR from 
splenocytes of Devic mice with or without EAE and single transgenic mice. Healthy 
or sick Devic mice and TCRMOG single transgenic mice expressed similar amounts of 
Foxp3. In contrast, IgHMOG mice expressed significantly higher amounts of Foxp3 
(Figure 5.26). 
However, this does not account for the variable expression of Foxp3 within the 
same individual and changes in expression before and after clinical EAE. To 
address this point, Foxp3 gene expression was determined by real-time quantitative 
PCR of PBMCs isolated from the same Devic mouse every week. Foxp3 gene 
expression in PBMCs was quite variable in these mice. During young age (around 4 
- 5 weeks) both sick and healthy Devic mice showed low levels of Foxp3 gene 
expression. On the one hand, Foxp3 expression was higher and increased over time 
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in Devic mice that did not develop spontaneous EAE. On the other, the majority of 
sick Devic mice expressed low levels of Foxp3 transcripts, which, interestingly, 
remained low over time (Figure 5.27). 
 
Figure 5.27  
Variable Foxp3 expression in sick and healthy Devic mice. (A) and (B) show the expression of Foxp3 
in PBMCs. Three sick and three healthy Devic mice were bled 4 times once a wk starting from 4 – 5 
wk of age, and Foxp3 expression was assessed by quantitative real-time PCR (A). Two healthy Devic 
mice were bled once every 2 wk, and Foxp3 expression was measured by real-time PCR (B). 
Relative expression values are expressed as percentage of endogenous GAPDH gene transcript ± 
SEM measured from triplicate samples. 
 
To confirm Foxp3 expression at the protein level, intracellular staining was 
performed. Foxp3 expression in splenocytes from relatively young (4 – 8 wk old) 
Devic mice was undetectable, perhaps due to the limits of detection of the assay. 
Nevertheless, 8-month-old healthy Devic mice clearly showed expression of Foxp3 
(2.6%), confirming the possibly protective role of Foxp3 expressing cells. Foxp3 
expression is variable even among the healthy Devic mice of the same age (Figure 
5.28).  
Foxp3-expressing regulatory cells are known to express GITR (glucocorticoid-
induced tumor necrosis factor receptor family-related gene) and CD25 (IL-2 receptor 
α chain). Blocking antibodies (anti-GITR; DTA-1, anti-CD25; PC61) against these 
molecules have been shown to deplete regulatory cells and promote autoimmunity.  
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Figure 5.28 
Intracellular Foxp3 expression in Devic splenocytes. Splenocytes from ~8-month-old (A and B) and 8- 
wk-old (C) Devic mice were stained with antibodies against the cell surface molecules CD25, CD4, 
and CD3. Intracellular Foxp3 staining was done after permeabilization and fixing of the cells. Shown 
are CD4+CD3+ gated cells expressing CD25 and Foxp3.  
 
The effect of the antibodies DTA-1 and PC61 on the proliferation of Devic 
splenocytes was measured. Anti-CD25 antibody (PC61) greatly diminished the 
proliferation induced by rMOG, and anti-GITR antibody (DTA-1) enhanced the 
proliferation, thus confirming the effectiveness of these antibodies on transgenic 
cells (Figure 5.29). 
 
Figure 5.29 
The effect of anti-CD25 and anti-GITR antibodies on proliferation. Devic splenocytes were left 
untreated or added to 10 µg/ml PC61 (anti-CD25) or DTA-1 (anti-GITR) and exposed to increasing 
concentrations of rMOG. Proliferation measured in triplicates by 3H-thymidine incorporation is 
expressed as mean cpm ± SEM. 
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These antibodies were administered to Devic mice, and their influence on disease 
incidence was observed. When administered to either young (3 – 4 wk-old) or adult 
(4 – 8 wk-old) mice, they did not have a major impact on the incidence and kinetics 
of clinical disease. The PC61 antibody treatment did not significantly affect clinical 
EAE compared to control Ig or PBS-treated mice. However, DTA-1 treatment 
enhanced the disease incidence (Table 5.7).  
 
Table 5.7 
Incidence of spontaneous EAE after depletion of regulatory T cells 
 
Healthy Devic mice (3 - 7 wk-old) were injected with 500 µg of the indicated antibody once a week 3 - 
4 times, and the incidence of spontaneous EAE was monitored.  
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6. Discussion 
 
MS is a complex CNS disorder that has multiple pathogenic manifestations but no 
known trigger. Although existing EAE models are important for studying the 
pathogenic mechanisms of MS, they do not reproduce human MS pathology in all its 
structural and clinical aspects. 
The double-transgenic mouse model presented here has several advantages. 
Foremost among them is that it recapitulates several pathological aspects of the 
human disease, Devic’s neuromyelitis optica, a variant form of MS. For this reason it 
is aptly termed, the “Devic mouse”. The pathological hallmark of Devic’s disease is 
the restricted localization of demyelinating lesions in the optic nerve and spinal cord 
(Cree et al., 2002). Devic mice show similar demyelinating lesions in the spinal cord 
and optic nerve, but not in the brain or cerebellum. Serological and clinical evidence 
suggest that B cells and autoantibodies are involved in Devic’s disease, and Ig 
deposition and eosinophilic infiltration are prominent features of its pathology 
(Lucchinetti et al., 2002). In the Devic mouse both MOG-specific B and T cells 
interact at multiple levels to precipitate EAE. Although eosinophilic infiltration was 
observed in some Devic mice, Ig deposition is rare. Another difference is sex bias. 
Many human autoimmune diseases including MS are more prevalent in females 
than males. Sex differences in susceptibility to autoimmune disease have also been 
reported in several mouse models. For example, female NOD mice are more 
susceptible than males to develop spontaneous diabetes (Kikutani and Makino, 
1992; Whitacre et al., 1999). Susceptibility to induced EAE is also characteristic of 
females in some inbred strains, most notably in SJL/J mice (Levine and Sowinski, 
1973; Papenfuss et al., 2004). Devic mice, however, do not show any sex bias in 
spontaneous EAE incidence or in kinetics. 
A second crucial feature of the Devic mouse is that it spontaneously develops 
EAE. Conventional EAE models suffer from many shortcomings, for example, the 
need to activate T cells before transfer or to use a strong adjuvant to artificially 
induce an immune response. In contrast, about 50% of the Devic mice develop 
spontaneous EAE at about 12 wk of age. Neither of the single transgenic parental 
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mice develops EAE within that time. Spontaneous, organ-specific autoimmune 
mouse models are rare. The non-obese diabetic (NOD) mouse (Makino et al., 1980), 
which spontaneously develops diabetes, is a widely studied spontaneous model of 
autoimmunity. Several transgenic and knock-out mice have been reported to 
develop spontaneous, organ-specific, and systemic autoimmune diseases 
(Burkhardt and Kalden, 1997). Spontaneous EAE was also reported in TCR 
transgenic mice for MBP in the context of I-Au (Goverman et al., 1993; Lafaille, 
2004), and PLP 139-151-specific TCR transgenic mice in the context of I-As. MBP- 
specific TCR transgenic mice developed EAE at variable frequencies, depending on 
the housing conditions or the absence of endogenous regulatory lymphocytes.  
Third, the Devic mouse is unique because of the presence of B and T cells that 
have same myelin autoantigen specificity. No other animal model has been reported 
to have such properties. The relevance of antigen specificity in spontaneous EAE 
was confirmed by two control breeding experiments. First, the breeding of IgHMOG 
transgenic mice with non-specific antigen ovalbumin (IgHMOG X OT-II) never showed 
any spontaneous EAE. Second, MOG-deficient Devic mice also did not develop 
CNS autoimmunity.  
The Devic mouse is being used to investigate several issues that remain open 
and may serve as a better model to study those issues.  
1. Triggers of spontaneous autoimmunity 
One major issue involves the triggers of spontaneous autoimmunity. They are 
currently at the forefront of autoimmune research. So far both positive and negative 
mechanisms have been proposed. Positive mechanisms include microbial antigens, 
which have the potential to initiate autoreactivity by molecular mimicry, by polyclonal 
activation of autoreactive lymphocytes, or by the release of previously sequestered 
antigens. Their relative involvement is still controversial. Goverman and colleagues 
have shown that 14 - 44% of MBP-specific transgenic mice develop spontaneous 
EAE when housed under conventional conditions, whereas none of these mice 
developed EAE under SPF conditions. However, in a follow-up study, they observed 
spontaneous EAE in about 15% of the mice under SPF conditions, and they linked 
microbial triggers to this development of spontaneous EAE (Brabb et al., 1997; 
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Goverman et al., 1993). The NOD mouse, in contrast, exhibits spontaneous diabetes 
more frequently when housed under SPF than under “dirty” conditions (Pozzilli et al., 
1993; Singh and Rabinovitch, 1993). The present study has shown that there is a 
similar incidence of EAE in Devic mice grown under conventional or SPF conditions. 
2. The site of priming of autoreactive lymphocytes 
It is commonly believed that the priming of autoreactive lymphocytes must occur 
in the peripheral lymphoid organs, since under normal conditions the BBB does not 
permit the passage of immune cells. Activated T cells express a set of adhesion 
molecules, which are important for their transmigration across the BBB. While the 
activation of lymphocytes in actively induced EAE occurs in the lymph nodes, the 
exact site of activation of T cells in human CNS autoimmune disease and in 
spontaneous animal models must still be identified. In a monkey model of EAE, it 
has been suggested that CNS antigen can be transported to the cervical lymph 
nodes, where it contributes to the priming of the autoreactive T cells (de Vos et al., 
2002). Besides the presence of APCs, an inflammatory milieu is necessary for this 
priming. A search for lymphocyte activation molecules in secondary lymphoid organs 
of healthy and sick Devic mice did not identify any distinguishable activation status 
of T or B cells. However, CNS infiltrated cells from the sick Devic mice upregulated 
several activation markers. This raises the question of the presence of (if any) 
putative triggering factors in the peripheral lymphoid organs of Devic mice. 
The transfer of CFSE-labeled lymphocytes confirmed that T cells are not activated 
in the peripheral lymphoid organs even during an ongoing inflammatory immune 
process. Both the proliferation and activation of transgenic T cells were only 
detectable in the CNS of sick Devic mice. It is not clear which APCs induce the 
activation of T cells. Recently, however, it was demonstrated that CNS-resident 
dendritic cells or microglia can activate autoreactive cells (Greter et al., 2005; 
Heppner et al., 2005). Furthermore, McMahon et al. showed that even during 
ongoing CNS inflammation the activation of PLP transgenic T cells occurred only in 
the CNS and not in the cervical lymph nodes or in other peripheral lymphoid organs 
(McMahon et al., 2005).  
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It is a well-documented fact that EAE can be induced in normal mice by 
autoantigen, mycobacteria, and adjuvant. Innate immune signals elicited on APCs 
through toll-like receptors exacerbate EAE in PLP-reactive transgenic mouse as well 
as in WT SJL/J mice (Waldner et al., 2004; Ichikawa et al., 2002). Microglia acting as 
CNS sentinels for danger signals have been shown to increase TLR expression in 
response to inflammatory mediators as well as microbial products (Olson and Miller, 
2004). Augmented TLR expression during EAE was observed within the CNS, even 
in the absence of any apparent microbial involvement (Prinz et al., 2006). However, 
in our preliminary experiments, the injection of Devic mice with TLR ligands failed to 
influence the disease incidence. 
3. The role of regulatory lymphocytes 
Autoaggressive T and B cells might be controlled by regulatory lymphocytes and 
hence autoimmunity could be facilitated by the depletion of regulatory cells. The 
presence of many types of regulatory cells has been shown in different models. 
Naturally occurring CD4+CD25+ regulatory T cells (Treg) are thought to control 
autoimmunity through multiple mechanisms (Sakaguchi, 2004). The adoptive 
transfer of CD4+CD25+ regulatory T cells conferred significant protection from clinical 
EAE (Kohm et al., 2002), and the depletion of putative regulatory cells from EAE- 
resistant B10.S mice (Reddy et al., 2005) or SJL/J mice exacerbated EAE (Kohm et 
al., 2004). However, both healthy and sick Devic mice harbored a very low 
frequency of CD4+CD25+ T cells (< 2%). Furthermore, the administration of depleting 
antibodies (anti-CD25 and anti-GITR) had only a marginal influence on the 
development of EAE. 
Foxp3, which encodes a transcription factor, is expressed in naturally arising 
regulatory T cells and is the only available specific marker for them (Hori et al., 
2003). The naturally occurring Foxp3 mutant scurfy mice or the targeted disruption 
of the Foxp3 gene led to a severe autoimmune syndrome (Fontenot et al., 2003). 
Splenocytes of young Devic mice expressed Foxp3 in amounts similar to that of 
TCRMOG splenocytes, but at much lower levels than single transgenic IgHMOG mice. 
This might partly explain why optic neuritis is observed in TCRMOG mice and EAE in 
Devic mice. Reduced Foxp3 expression might be due to a restricted endogenous 
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TCR-encoded repertoire. The higher frequencies of EAE observed after removal of 
endogenous T cells (putative regulatory), cells of MBP-specific TCR transgenic 
mice, and the transfer of polyclonal T cells completely prevented EAE (Lafaille et al., 
1994). Interestingly, preliminary experiments showed that Devic mice with EAE had 
even more reduced expression of Foxp3 in PBMCs than healthy mice over time. 
Conversely, 8-month-old resistant mice expressed much higher levels of Foxp3 in 
the spleen. The elevated expression of Foxp3 found in some sick mice, however, 
suggests that additional factors are involved. 
4. The complex role of B cells and antibodies 
Although MS is considered to be mainly a T cell-mediated disease, evidence is 
emerging that, at least in one subset of MS cases, B cells and antibodies are 
involved (Lassmann et al., 2001). This applies also to patients with Devic’s disease 
who have pronounced Ig reactivity co-localizing with complement activation at sites 
of blood vessel damage (Lucchinetti et al., 2002). Indeed, B cells, plasma cells, and 
oligoclonal Ig bands are quite common components of MS lesions (Baranzini et al., 
1999; Esiri, 1980; Walsh and Tourtellotte, 1986).  
EAE models have so far been used to study T cell responses in CNS 
autoimmunity. Studies on neonatally B-cell depleted mice (Myers et al., 1992) and B 
cell-deficient transgenic µMT mice (Wolf et al., 1996) have shown that B cells in 
general might play a significant role in the pathogenesis of EAE. However, the 
contribution of autoantigen-specific B cells has been largely ignored due to the lack 
of suitable animal models. Here the Devic mice offer unique advantages as a 
double-transgenic model with T and B cells specific for the same myelin autoantigen, 
MOG. The interaction of autoreactive B and T cells can occur at multiple levels. 
Antigen-specific B cells can act as efficient APCs. By virtue of the presence of 
antigen-binding receptor on the surface, B lymphocytes are able to efficiently 
capture specific antigen and present it to antigen-specific T cells (Rock et al., 1984; 
Zimecki et al., 1988; Lanzavecchia, 1985). This is definitely the case in Devic mice. 
When Devic mouse B cells were mixed with MOG-specific T cells, they greatly 
enhanced the proliferation of T cells, even when recombinant MOG protein was 
highly diluted, but not with the immunodominant MOG 35-55 peptide. This is 
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consistent with the fact that the transgenic H chain binds only a conformational 
epitope of MOG but not the MOG 35-55 peptide (Litzenburger et al., 1998). The 
increased response, however, cannot be attributed to the increased MOG-binding 
activity of transgenic B cells, since both single transgenic mice and Devic mice B 
cells showed similar MOG-binding activity. This result certainly has in vivo 
relevance; the availability (if any) of the autoantigen during the initial phase of 
disease would be a critical factor. The significant role of antigen presentation by 
MOG-specific B cells in the pathogenesis is further supported by the finding that the 
transfer of MOG-incubated IgHMOG B cells to TCRMOG single-transgenic mice was 
sufficient to induce spontaneous EAE. These results are consistent with the 
proteoglycan-induced arthritis model, in which antigen presentation of antigen-
specific B cells is important for the induction of arthritis (O'Neill et al., 2005).  
MOG-specific B cells in Devic mouse not only present antigen to T cells but also 
respond to MOG by proliferation and activation. The interaction between T and B 
cells is an active co-operation, since irradiation of the transgenic B cells abolishes 
the enhanced proliferation of mixed cultures. An effective humoral response also 
requires that the B cells receive contact-mediated signals from activated T cells 
(Bishop and Hostager, 2001). B7 family ligand and receptor pairs expressed on B 
and T cells are known to serve as potential mediators of such interactions 
(Greenwald et al., 2005; Sharpe and Freeman, 2002).  
ICOS expressed on activated T cells provides a co-stimulatory signal to B cells 
and induces isotype switching (McAdam et al., 2001; Hutloff et al., 1999). ICOS has 
also been shown to be important in the immunopathogenesis of EAE (Rottman et al., 
2001). Devic mouse T cells rapidly upregulated ICOS after MOG activation. This 
might be one of the important factors responsible for the spontaneous isotype 
switching as well as spontaneous EAE observed in Devic mice. In addition, while B 
cells of single transgenic mice downregulated ICOSL rapidly and completely, Devic 
mouse B cells downregulated it only partially. This would lead to a sustained 
activation of T and B cells. It was also shown previously that the ICOSL expression 
on B cells is completely extinguished after antigen engagement without the help of T 
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cells, and signaling through CD40 mediated by T cells restored ICOSL expression 
(Liang et al., 2002).  
Furthermore, the negative co-stimulatory molecule PD-1 and its ligand PDL-1,-2 
interactions inhibit the proliferation and effector cytokine production of T cells 
(Sharpe and Freeman, 2002). PD-1 was upregulated only on a fraction of Devic T 
cells, but on much larger amounts of Devic B cells than in single transgenic mice 
after MOG activation. The rapid upregulation of PD-1 on Devic T cells not only 
confirms the antigen-specific interaction between B and T cells but also the 
presence of negative regulatory mechanisms that limit the activation of self-reactive 
T cells. In addition to the expression of co-stimulatory molecules, Devic lymphocytes 
are also rapidly activated by MOG. This supports the hypothesis that minimal 
antigen doses would be sufficient to rapidly activate autoreactive T cells in vivo. 
 Another cardinal feature of antigen-specific B cells is the production of 
autoantibodies, which either directly induce tissue damage or form an immune 
complex and mediate complement activation (Martin and Chan, 2004). Furthermore, 
T-B cell interactions play a critical role in controlling Ig affinity maturation and isotype 
switching. The cytokines produced by T cells can be divided into Th1 or Th2, which 
mediate distinct effector functions (Gor et al., 2003). They might help B cells to 
undergo class switching. Anti-MOG Igs were present in the Devic mouse. B cells 
from the Devic mouse, but not IgHMOG X OT-II or IgHMOG knock-in mice, underwent 
spontaneous isotype switching from IgM to IgG1. This is commonly observed in Th2 
immune conditions. Surprisingly, Devic mice splenocytes produced Th1 cytokines 
(IFNγ, IL-2) in response to MOG stimulation in vitro, and low levels of the Th2 
cytokines IL-5, but not IL-4. IL-5 is a well-known cytokine that helps B cells to switch 
to IgG1 and IgE (Purkerson and Isakson, 1992), but its low level in Devic mice 
suggest that additional factors must contribute to the isotype switching. In principle, 
both T cells and B cells can produce cytokines. Intracellular cytokine staining after 
MOG stimulation showed that only T cells (but not B cells) produced Th1 cytokines. 
Consistent with these in vitro observations, only Th1 cytokines were present in the 
spinal cord of sick Devic mice; Th2 cytokines were not.  
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Ig isotype switching is considered to be a regulated event during which B cells 
bind antigen and present it to T cells, which in turn help the B cells. This 
conventional dogma is challenged by the fact that MOG-deficient (MOG-/-) Devic 
mice also showed isotype switching that was indistinguishable from MOG-sufficient 
(MOG+/+) Devic mice. This raises the question of a putative cross-reactive antigen 
that links MOG-specific T and B cells in vivo or perhaps the MOG-deficient mouse is 
an incomplete knock-out mouse. It has been postulated that a self-antigen other 
than MOG must cross-link to induce receptor editing (Litzenburger et al., 2000). 
Interactions between CD40 and CD154 (CD40L) provide a number of signals that 
regulate activation of T and B cells as well as isotype switching (Quezada et al., 
2004). Therapeutic blockade with CD40L-specific antibody has been shown to 
ameliorate EAE (Howard et al., 1999). In Devic mice, the blockade of CD40-CD40L 
interaction neither prevented spontaneous isotype switching nor affected EAE 
development. 
The definitive involvement of MOG-specific B and T cells in spontaneous EAE has 
been clearly indicated by the induction of EAE after BM reconstitution. Furthermore, 
the ability of naive splenocytes obtained from young healthy Devic mice to transfer a 
similar clinical and histopathological EAE into RAG-/- mice suggests that MOG-
specific T and B cells do interact to precipitate spontaneous EAE. It is nevertheless 
still not known, where and how the entire disease process is initiated. 
In summary, the Devic mouse model described here has several salient features. 
The peculiar localization of lesions in the optic nerve and the spinal cord differs from 
the classic EAE models and strikingly resembles Devic’s neuromyelitis optica in 
humans. The factors that determine this selective attack are not known. Presumably, 
target autoantigen, genetic factors, and the inherent leakiness of the BBB at the 
optic nerve and spinal cord may play a role in directing the autoimmune 
lymphocytes. MOG-induced EAE in BN rats favors antibody response and also 
produces a chronic demyelination, most frequently in the spinal cord and optic 
nerve. In contrast, immunization of dark agouti (DA) rats with MOG results in 
inflammation throughout the CNS (Storch et al., 1998). Furthermore, MHC and 
MHC-linked genes strongly influence the disease severity and clinical course 
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(Stefferl et al., 1999). The TCRMOG (2D2) mice used in the current study frequently 
showed isolated optic neuritis, but rarely EAE (Bettelli et al., 2003). In a recent study, 
aquaporin-4 binding antibodies were described in about 30% of the sera of patients 
with Devic’s disease. But the widespread expression of AQP4 (Badaut et al., 2002) 
does not coincide with the restricted lesion distribution in NMO patients (Lennon et 
al., 2005). 
Although many questions await definite answers, the Devic mouse is the first CNS 
autoimmune model that shows the interaction of antigen-specific B and T cells. The 
MOG-specific B cells can efficiently bind MOG and present it to the MOG-specific T 
cells. The anti-MOG autoantibodies can also have direct access to the MOG present 
on the membrane and induce damage. As a model of spontaneous immunity, the 
Devic mouse may prove instrumental in finally elucidating the triggering factors of 
autoimmune disease and for validating novel therapies of autoimmune CNS disease.
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8. Appendices  
8.1 Abbreviations 
aa    Amino acid 
ABTS   2, 2’-Azino-bis (3-ethyl-benzthiazoline-6-sulphonic acid) 
APC    Antigen presenting cell 
ASCs   Antibody secreting cells 
BBB    Blood brain barrier 
BCR    B cell receptor 
BM    Bone marrow 
CD    Cluster of differentiation 
CFA    Complete Freund’s adjuvant 
CFSE   Carboxy-fluorescein diacetate succinimidyl ester 
CNS    Central nervous system 
cpm    Counts per minute 
CSF    Cerebrospinal fluid 
CTLA-4   Cytotoxic T-lymphocyte-associated protein 4 
EAE    Experimental autoimmune encephalomyelitis  
EBV    Epstein-Barr virus 
ELISPOT  Enzyme-linked immunospot 
FACS   Fluorescence activated cell sorting 
FCS    Fetal calf serum 
GITR Glucocorticoid-induced tumor necrosis factor receptor 
 family-related gene 
H & E   Hematoxylin and eosin 
h     Hour 
HBV-P   Hepatitis B virus polymerase 
HHV    Human herpes virus 
HLA    Human leukocyte antigen 
HSV    Hepes simplex virus 
i.p     Intraperitoneal 
i.v     Intravenous 
ICOS    Inducible co-stimulator  
ICOSL    Inducible co-stimulator ligand 
Ig     Immunoglobulin 
IgHMOG MOG-specific Ig heavy chain knock-in mice on C57BL/6 background  
IPTG   Isopropyl thiogalactoside  
KO    Knockout 
LDAO   N, N-dimethyldodecylamine-N-oxide 
LFB    Luxol fast blue 
LPS    Lipopolysaccharide 
MAG    Myelin-associated glycoprotein 
MBP    Myelin basic protein  
MHC    Major histocompatibility complex 
Min    Minutes 
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MOBP   Myelin associated oligodendrocytic basic protein 
MOG   Myelin oligodendrocyte glycoprotein 
MS    Multiple sclerosis 
NMO   Neuromyelitis optica 
NOD Non-obese diabetic 
OSP    Oligodendrocyte specific protein 
OT-II Ovalbumin specific TCR transgenic mice on C57BL/6 background 
PBMCs   Peripheral blood mononuclear cells 
PBS    Phosphate buffered saline 
PCR    Polymerase chain reaction 
PD-1    Programmed death-1 
PD-L    Programmed death-1 ligand 
PLP    Proteolipid protein 
PP-MS   Primary progressive MS 
PR-MS   Progressive-relapsing MS 
RAG    Recombinase activating gene 
RBCs   Red blood cells 
rMOG   Recombinant MOG 
RR-MS   Relapsing-remitting MS 
s.c    Subcutaneous 
SD    Standard deviation 
SEM    Standard error of the mean 
SPF    Specific pathogen free 
SP-MS   Secondary progressive MS 
TCR    T cell receptor 
TCRMOG  MOG-specific TCR transgenic mice on C57BL/6 background 
TLR    Toll-like receptor 
WT    Wild-type 
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